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To sustain the health and viability of renal transplants, adherence to immunosuppressant 
therapy (IST) medications is critical.  Studies continue to identify decreased adherence rates as 
time from transplant increases (Chisholm-Burns, Kwong, Mulloy & Spivey, 2008; Chisholm, 
Lance, Mulloy, 2005; Chisholm, Mulloy, & DiPiro, 2005; Nivens & Thomas, 2009).  While 
previous research has explored the effect of variables known to influence IST adherence in adult 
renal transplant recipients, limited studies have explored these variables in a population of renal 
transplant recipients with longer time posttransplant intervals.  The purpose of this study was to 
examine demographic variables, time posttransplant, immunosuppressive agents, health beliefs, 
social support, and symptom experience and test their relationship to adherence in a population 
of long-term renal transplant recipients. 
A cross-sectional correlational design was used to collect data from a convenience 
sample of 98 adult renal transplant recipients who were three or more years from transplant.  
Participants completed five instruments: 1) demographic survey, 2) the Beliefs About Medicines 
Questionnaire (BMQ), 3) the Medical Outcomes Study (MOS) Modified Social Support Survey  
(MSSS), 4) the Basel Assessment of Adherence with Immunosuppressive Medication Scales 
(BAASIS), and 5) the Modified Transplant Symptom Occurrence and Symptom Distress Scale-
59R (MTSOSD-59R).  A composite adherence score (CAS) consisting of a self-report measure 
of adherence (BAASIS), nontherapeutic serum drug assay, and collateral report of adherence as 
provided by two transplant clinic professionals was used to determine final adherence group 
classification (adherent/nonadherent).  Analysis of the relationship between all independent 
variables and adherence was conducted using Spearman’s rho correlation coefficient.  Mean 





compared between age, gender, and time posttransplant groups using independent-samples t 
tests.  A logistic regression prediction of probability was conducted to determine which of the 
variables that demonstrated a significant relationship to adherence were most predictive of 
adherence. 
Of the total sample population (N = 98), 39.8% (n = 39) were classified as adherent and 
60.2% (n = 59) were nonadherent.  Results demonstrated no significant relationship between age 
(continuous variable), time posttransplant, immunosuppressant medications (measured by a 
medication complexity index), health beliefs, symptom experience, and adherence.  Weak, but 
significant relationships between age groups (r = -.213, p=.035), tangible social support (r = 
.215, p =.017), emotional informational social support (r = .274, p = .003), positive social 
interaction support (r = .199, p = .025), total overall social support (r = .274, p =.003) and 
composite adherence group classification were found.  Older participants (> 55 yrs) were 
significantly less adherent than younger (< 54 yrs) participants.  Mean scores for emotional / 
informational (EMI), positive social interaction (POS), and total social support (MSSS) were 
significantly lower in nonadherent participants.  Regression results indicated the overall model of 
two predictors (age grouped [< 54 yrs; > 55 yrs] and EMI social support subscale) was 
statistically reliable in distinguishing between adherent and nonadherent participants (-2 Log 
Likelihood 116.244; Goodness-of-Fit x2 (2) = 13.664, p = .001), correctly classifying 69.1% of 
the cases.   
Findings from this study contribute to the body of research exploring predictors of 
immunosuppressant adherence in long-term renal transplant recipients.  Data suggest both 
younger age (< 55) and categories of social support predict adherence in long-term renal 
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 To sustain the health and viability of renal transplants, adherence to a lifelong regimen of 
immunosuppressant therapy (IST) is critical.  Within the adult renal transplant population, 
nonadherence to IST medications has been identified as contributing substantially to increased 
risk of both acute and late acute rejection as well as increased graft loss with odds of graft failure 
increasing in recipients identified as nonadherent (Butler, Roderick, Mullee, Mason, & Peveler, 
2004; Nevins & Thomas, 2009).  In addition, studies continue to identify decreased adherence 
rates as time posttransplant increases (Chisholm-Burns, Kwong, Mulloy & Spivey, 2008; 
Chisholm, Lance, Mulloy, 2005; Chisholm, Mulloy, & DiPiro, 2005; Nivens & Thomas, 2009).  
While advances in medicine and the development of more effective IST regimens have resulted 
in one year survival rates that exceed 90%, efforts continue to focus on reducing the incidence of 
acute rejection and improving long-term outcomes (United States Renal Data Systems [USRDS], 
2010).  Given the association of increased time posttransplant with IST nonadherence, 
exploration of factors that contribute to long-term IST adherence is warranted if long-term renal 
transplant outcomes are to improve. 
Background 
 
 Within the adult renal transplant population, IST nonadherence rates vary widely (8%-
65%) with an average self-reported nonadherence rate of 28% (Denhaerynck, et al. 2005).  A 





recipients concluded immunosuppressant nonadherence to be highest in renal transplant 
recipients (36%); the rate was more than twice the rate observed in heart recipients, and over five 
times greater than liver recipients (Dew et al. 2007).  In addition, individual medical costs 
associated with persistent low adherence increased individual 3 year medical costs by over 
$12,000 (Pinsky et al. 2009).  
Nonadherence with IST therapy is identified as contributing substantially to a median 
36% (14%-65%) of graft loss (Butler, Roderick, Mullee, Mason, & Peveler, 2004).  In a 
retrospective cohort study of 15,525 renal transplant recipients, the incidence of graft failure was 
11.5% in recipients identified as poorly adherent (Pinsky, et al. 2009).  Even minor deviations in 
IST dosing schedules have been associated with the development of adverse outcomes and graft 
rejection (Nevins & Thomas, 2009; Nevins, Kruse, Skeans, & Thomas, 2001; Schäfer-Keller, 
Lyon, Van-Gelder, & De Geest, 2006).  In a retrospective analysis of IST dose reduction and 
discontinuation, dose reductions greater than 50% were associated with an increased hazard of 
graft loss while dose discontinuation resulted in an 8-fold increase in graft loss (Takemoto, 
Pinsky, Schnitzler, Lentine, Willoughby, Burroughs, & Bunnapradist, 2007). 
The World Health Organization (WHO, 2003) in defining adherence, captured the 
multidimensional nature of the concept.  Categories of influencing variables included in the 
definition were socioeconomic, patient-related, condition-related, therapy-related, and healthcare 
system/healthcare team-related variables.  All categories of variables have been explored within 
the adult renal transplant population. 
Of the therapy-related variables known to influence IST adherence, increased time from 





Kwong, Mulloy, & Spivey, 2008; Chisholm, Mulloy, & DiPiro, 2005; Chisholm, Vollenweider, 
Mulloy, Jagadeesan, Wynn, Rogers, et al., 2000; Ichimaru, Kakuta, Okumi, Imamura, Isaka, 
Nonomra, Kojima, Okuyama, & Takahara, 2008; Nevins & Thomas, 2009; Vasquez, Tanzi, 
Benedetti, & Pollak, 2003).   While substantial nonadherence with  a single IST medication 
(18%) has been identified as early as one month following discharge (Nevins, Kruse, Skeans, & 
Thomas, 2001),  persistent reductions in mean adherence rates for the same IST medication has 
been found to continue up to four years following initial transplant, supporting results obtained 
in earlier studies (Nevins & Thomas, 2009).  In addition, one isolated study classified time 
posttransplant in quartiles.  Authors concluded quartile 1 (< 4 years posttransplant) as being 
significantly associated with higher adherence and noted for every year of increase in time 
posttranplant, adherence decreased by 0.3% (Chisholm-Burns, et al. 2008).  Increased time 
posttransplant remains a nonmodifiable therapy-related factor associated with increased risk of 
nonadherence to IST medications. 
Other variables identified as influencing adherence-immunosuppressant therapy, beliefs 
about medicines, social support, and symptom experience- have been explored in a few recent 
studies.  In addition, studies exploring these variables include sample populations with recipients 
as early as six months to two years posttransplant.  To date, no study has explored these 
variables in a group of renal transplant recipients identified as “long-term” yielding support 







Statement of Problem  
 
Despite the performance of over 16,000 kidney transplants in 2010, over 96,000 patients 
currently await renal transplantation in the United States (United Network for Organ Sharing 
[UNOS], 2009).  Given the current shortage of available organs, efforts continue to focus on 
improving long-term outcomes.  While previous research has explored the effect of all categories 
of influencing variables on IST adherence in adult renal transplant recipients, limited studies 
have explored these variables in a population of renal transplant recipients with longer time 
posttransplant intervals.   
Study Purpose/Aim 
 
The purpose of this study was to examine demographic variables, time posttransplant, 
immunosuppressive agents, health beliefs, social support, and symptom experience and test their 
relationship to adherence based upon the Health Decision Model (Eraker, Becker, Strecher, & 
Kirscht, 1984).   
Definition of Terms 
 














Age Age of the participant in years at the time of 
study enrollment. 
Younger = < 54 years; older = > 55 years of 
age.  
Date of birth as measured by a 
demographic questionnaire.  Age in 
years at the time of study enrollment 
was calculated using date of study 
enrollment and date of birth. 
Long-Term 
 
Long-term was defined as three or more years 
from transplant. 
Long-term was defined by the date 
of initial transplant as measured by a 
demographic questionnaire.   
Time Posttransplant Time posttransplant was defined as the total 
number of years since the patient’s date of 
renal transplantation. 
Time posttransplant was measured 
by a demographic questionnaire. 
Time posttransplant in years was 
calculated using both the date of 
study enrollment and the date of 
renal transplantation. 
Immunosuppressive Agents Immunosuppressive agents were defined as 
the names of medication the patient is taking 
for the purpose of immunosuppression. 
Immunosuppressive agents were 
identified by a demographic 
questionnaire and included the 
medication names.  Medication 
complexity was measured using a 
calculated medication complexity 
index-the product of the total 
number of IST medications, number 
of pills taken per day, and the 
number of times per day taking 
medications. 
Health Beliefs Health beliefs were defined as personal 
convictions that influence individual health 
behaviors (Moorhead, Johnson, Maas, & 
Swanson, 2008). 
Health beliefs were measured by the 
Beliefs about Medicines 
Questionnaire [BMQ) (Horne, 
Weinman, & Hankins, 1999).  
Possible scores for both BMQ 
subscales range from five to 25 with 
















Social Support Social support was defined as the existence or 
availability of a person or network of people 
that rely, care, and love an individual and on 
whom that same individual can rely (Sarason, 
Levine, Basham, & Sarason, 1983). 
Social support was measured by the 
18 item Medical Outcomes Study 
(MOS) Modified Social Support 
Survey (MSSS) subscales and total 
instrument scores (Sherbourne & 
Stewart, 1991) The18 items 
represent the multiple dimensions of 
social support-tangible, affectionate, 
emotional / information, positive 
social interaction.  Possible scores 
range from 0-100 with higher scores 
indicating greater perceived support. 
Symptom Experience 
  
Symptom experience was defined as both 
symptom occurrence representing the 
cognitive component of the frequency, 
severity and duration of symptoms, and 
distress representing the emotional burden 
that results (Kugler, Geyer, Gottlieg, Simon, 
Haverich, & Dracup 2009). 
Symptom experience was measured 
by the Modified Transplant 
Symptom Occurrence and Symptom 
Distress Scale (MTSOSD-59R) 
(Dobbels, Moons, Abraham, Larsen, 
Dupont & De Geest, 2008).  Ridit 
scores were calculated to rank order 
symptom occurrence and symptom 
distress.  Overall individual 
symptom occurrence and symptom 
distress ridit scores were compared. 
Immunosuppressant 
Nonadherence 
Immunosuppressant nonadherence was 
defined as “deviation from the prescribed 
medication regimen sufficient to influence 
adversely the regimen’s intended effect” 
(Fine, Becker, De Geest, Eisen, Ettenger, et 
al., 2009, p. 36). 
Immunosuppressant nonadherence 
was measured as a composite 
adherence score that consisted of 
self-reported nonadherence as scored 
on the Basel Assessment of 
Adherence with Immunosuppressive 
Medications Scale (BAASIS), 
collateral-reported nonadherence of 
two clinicians, and nontherapeutic 
assay variability.  Participants were 











Research Question and Hypotheses 
 
Based on the Health Decision Model and review of the literature, the primary research 
question to be addressed was which of six predictor variables-demographic variables, time 
posttransplant, immunosuppressive agents, health beliefs, social support, and symptom 
experience-are most influential in predicting IST adherence in long-term adult  renal transplant 
recipients?  The following hypotheses were tested in this study: 
Hypothesis 1 
There will be a significant negative relationship between the predictor variable of time 
posttransplant as measured in years and composite adherence group classification. 
Hypothesis 2 
There will be a significant relationship between the predictor variable of age as measured 
in years and composite adherence group classifications. 
Hypothesis 3 
 There will be a significant relationship between medication (IST) complexity index  
scores and composite adherence group classifications. 
Hypothesis 4 
There will be a significant difference in IST complexity index scores between composite 






There will be a significant relationship between the predictor variable of health beliefs as 




 There will be a significant difference in BMQ Necessity subscale, BMQ Concerns  
subscale, and BMQ Necessity/Concerns differential scores between composite adherence group  
classifications. 
Hypothesis 7 
There will be a significant positive relationship between the predictor variable of social 
support as measured by total MSSS scores and composite adherence group classifications.  
Hypothesis 8 
There will be a significant difference in MSSS subscale and total scale scores between 
composite adherence group classifications. 
Hypothesis 9 
There will be a significant negative relationship between the predictor variable of 







 There will be a significant difference in MTSOSD-59R total ridit scores between 
composite adherence group classifications. 
Study Significance 
 
As time posttransplant increases, follow-up care shifts from the acute care phase provided 
by transplant clinics during the first year following transplantation to long-term health promotion 
and maintenance provided by primary healthcare providers outside of the transplant clinic 
setting.  Having an understanding of the modifiable factors that contribute to successful long 
term IST adherence can guide practitioners in developing and implementing appropriate 
interventions to sustain long- term IST adherence improving long-term graft outcomes. 
 Nonadherence with immunosuppressive medication in the adult renal transplant 
population impacts the health and viability of graft outcomes due to a variety of influencing 
factors.  As the focus shifts to improving long-term graft outcomes, comprehensive exploration 
of risk factors for adherence in long-term populations helps delineate risk profiles.  Research 
regarding the influence of risk factors for nonadherence in long-term renal transplant populations 
has yet to be conducted and this study will add to the current body of knowledge.  Chapter 2 
provides a review of literature relevant to the problem under study, illustrates the framework that 
guided the study, and identifies gaps in the literature to be addressed by the current study.  
Chapter 3 addresses methods used to carry out the research, while Chapters 4 and 5 present 





CHAPTER TWO:  LITERATURE REVIEW 
 
To determine the state of the science of IST adherence research within the adult renal 
transplant population, a review of Cumulative Index to Nursing and Allied Health Literature 
(CINAHL), PubMed, and PsychInfo databases was conducted using the key search terms of 
adherence, immunosuppressant, medication, and renal transplant.  Secondary searches were 
conducted from the reference lists of selected articles. While all studies selected were published 
in the English language, priority was given to studies that were published within the last 10 
years.  Works older than 10 years considered seminal studies were included in the review.  
Studies that explored variables within European populations were included if literature on the 
variable under study was limited.   Examination of previous research regarding IST adherence 
definition and measurement, prevalence and outcomes, and categories of determinants identified 
gaps in the current body of knowledge to be addressed by the proposed study. 
Defining Adherence 
 
While medication adherence rates of 80% are often cited as acceptable across many 
illness categories (Osterberg & Blaschke, 2005), a consensus definition of what constitutes 
optimum adherence in adult renal transplant recipients remains elusive.  The lack of a clinically 
meaningful definition of adherence prevents both the identification of the degree of adherence 
necessary to achieve desired pharmacological effects, and the degree of subclinical nonadherence 
that increases the risk of adverse outcomes (acute rejection, graft loss).  In light of the lack of a 





adherence into an “all or nothing” phenomenon (adherent, nonadherent).  Lost in the 
dichotomization of the concept of adherence are the dimensions of medication taking (taking, 
timing, drug holidays, and dose reductions) that contribute to the multidimensional nature of the 
phenomenon.   
While multiple studies exploring the prevalence of IST nonadherence in adult renal 
transplant recipients have selected 80% adherence as the degree distinguishing adherers from 
nonadherers (Chisholm, Lance, & Mulloy, 2005; Chisholm, et al., 2000; Hilbrands, Hoitsma, & 
Koene, 1995), the majority of prevalence studies have operationalized  IST nonadherence as the 
quantity and frequency of missed doses as measured using self-report (De Geest et al., 1995; 
Denhaerynck et al., 2006; Frazier, Davis-Ali, & Dahl, 1994; Ghods, Nasrollahzadeh, & Argani, 
2003; Hardstaff, Green, & Talbot, 2003; Raiz, Kilty, Henry, & Ferguson, 1999; Teixeira de 
Barros & Cabrita, 2000; Vasquez, Tanzi, Benedetti, & Pollak, 2003).  A meta-analysis of 36 
studies by Butler, Roderick, Mullee, Mason, and Peveler (2004) identified the most common 
definition of nonadherence as missing, forgetting, or altering of a dose at least once per month.  
Further complicating formulation of a consensus definition is a lack of clarification of what 
constitutes a “late” or “missed” dose.  While a few studies have defined the timing associated 
with a “late” dose as being ingested 2 to 2.5 hours beyond the scheduled time (Schmid-Mohler, 
Thut, Wüthrich, Denhaerynck, & De Geest, 2010; Sketris, Waite, Grobler, West, & Gerus, 1994; 
Teixeira de Barros & Cabrita, 2000), no studies to date conducted with the adult renal transplant 
population have explored clinician and/or patient conceptualizations of a “missed” dose. 
The phenomenon of nonadherence has been described using four characteristics:  timing, 





Mirroring the six patterns of medication adherence noted among other chronic illness categories 
(Osterberg & Blaschke, 2005) occasional nonadherence has been further delineated into three 
subcategories:  patients having near perfect adherence, patients adherent to nearly all doses but 
with timing irregularities, and patients missing an occasional dose.  Intermittent nonadherence 
was defined further as patients taking drug holidays 3-4 times yearly.  Persistent nonadherers 
were further defined as patients taking drug holidays monthly or more often, and complete 
nonadherers were identified as patients taking few or no doses of immunosuppressants (Hansen, 
et al., 2007).   In addition, Hansen et al. (2007) defined the diagnostic certainty of nonadherence 
as definite (direct admission of nonadherence by patient), probable, possible or unlikely, 
depending upon the evaluation method. 
A seminal study conducted by Greenstein and Siegal (2000), identified three profiles of 
nonadherent patients.  Accidental nonadherers, accounted for the majority of nonadherence in 
the study population (47%) and included patients who simply forgot to take IST medications. 
Invulnerable nonadherers, accounted for 28% of the study population and included renal 
transplant recipients guided by the belief they do not need to take their medications regularly.  
Decisive nonadherers, those patients who employed independent decision making habits 
ignoring the need for medications, accounted for 25% of the sample population.   
Recent studies have attempted to more clearly capture the dimensions of medication 
adherence behaviors.  A longitudinal study by Russell et al. (2006) of 44 adult renal transplant 
recipients identified four patterns of  IST adherence:  1) taking medications on time, 2) taking 
medications on time with late / missed doses, 3) rarely taking medications on time, and 4) taking 





cohort study conducted by Denhaerynck et al. (2007) captured similar patterns of nonadherence 
while studying the prevalence of IST nonadherence in 249 adult renal transplant recipients by 
exploring the percentage of  taking adherence (number of prescribed doses),  dosing adherence 
(days with correct dosing), timing adherence (taken within 25% of prescribed intervals), and 
drug holidays.  With the advent of more self-report adherence instruments measuring all 
dimensions of medication taking-timing, taking, drug holidays (missed, omitted) and dose 
reduction-more studies exploring determinants of adherence are capturing the entire nature of the 
concept. 
Current scholarly activities conducted within the transplant population have worked 
toward the formulation of solutions to address issues of definition and measurement in IST 
adherence research.  A more succinct definition of nonadherence, intended to better represent the 
dynamic nature of a patient’s medication taking behavior, emerged during a consensus 
conference on nonadherence to immunosuppressant medications (Fine, Becker, De Geest, Eisen, 
Ettenger et al, 2009).  Understanding that satisfactory adherence results when gaps between 
dosing history and the prescribed regimen have no effect on clinical outcomes, experts have 
conceptually defined nonadherence as “deviation from the prescribed medication regimen 




IST adherence studies have used both direct and indirect methods of measurement, each 





urine biological drug assays, biological markers), have the disadvantage of being inconvenient to 
the patient, influenced by increased adherence prior to sampling, affected by variations in 
individual metabolism, and at times, prone to lab error (Chisholm, 2002; Hansen, et al. 2007).  
Assays obtained for medications with a short half-life may only provide information about 
patterns of adherence over the prior few days with no information regarding long-term 
adherence.  In addition, therapeutic monitoring of IST medications such as mycophenolate 
mofetil (Cellcept) requires multiple blood samples during dosing intervals leading to increased 
costs, patient inconvenience, and limited feasibility across clinical settings (Jeong & Kaplan, 
2007).  Indirect measurement methods (patient self-report, collateral reports, prescription refill 
rates, pill counts, electronic drug monitoring, health outcomes), while often more simple and 
feasible, are not without disadvantages.  Patients often under report nonadherence, prescription 
refill rates fail to provide information related to characteristics of nonadherence; pill counts fail 
to consider multiple sources of medication; and electronic monitoring fails to prove ingestion 
(Chisholm, 2002; Hansen, et al. 2007).   
Electronic monitoring, frequently considered the gold standard measure of adherence, has 
limitations that challenge both internal and external measurement validity.  A study by 
Denhaerynck et al. (2008) examined assumptions needed for internal and external validity of 
electronic monitoring measurement.  The study tested validity through evaluation of:  1) correct 
functioning of electronic monitoring equipment, 2) correspondence of cap openings with actual 
dose intake, and 3) the influence of electronic monitoring on a patient’s normal adherence 
behavior.  Several assumptions of internal and external validity were not satisfied:  1) equipment 





of patients, and 3) adherence decreased over 5 weeks indicating an intervention effect of the 
measurement method (Denhaerynck et al., 2008). 
Despite the increased use of electronic monitoring, the majority of studies continue to 
rely heavily on self-report measures of adherence (surveys, questionnaires, interviews) (Brown et 
al., 2009; De Geest et al., 1995; Denhaerynck et al. 2007; Frazier et al. 1994; Ghods et al. 2003; 
Goldfarb-Rumyantzev, Wright, Ragasa, Ostler, Van Orden, Smith et al., 2011; Greenstein & 
Siegal, 1998; Kalil, Heim-Duthoy, & Kasiske, 1992; Nevins & Thomas, 2009; Raiz et al. 1999; 
Sharma, Gupta, Tolani, Rathi, & Gupta, 2000; Sketris, Waite, Grobler, West, & Gerus, 1994; 
Teixeira de Barros & Cabrita, 2000; Vasquez, Tanzi, Benedetti, & Pollak, 2003).  Though prone 
to response bias and criticized for providing little insight into adherence characteristics, self--
report measures of adherence are recognized as the most feasible method of monitoring 
adherence (Butler, Peveler, Roderick, Horne, & Mason, 2004).  A study comparing                   
self-report adherence with electronic measurement concluded that self-report adherence, 
conducted in the setting of a confidential interview, to be the better measure for detecting missed 
doses and erratic dose timing (Butler, et al. 2004).  In addition, a recent meta-analysis of 147 
studies conducted within the solid organ transplant populations concluded self-report 
assessments of adherence to yield the highest rates of nonadherence (Dew et al. 2007). 
To date, no measure of adherence (direct, indirect) has emerged as a gold standard.  
Current literature supports the use of a combination of measurement methods to increase 
diagnostic accuracy of subclinical nonadherence (Butler, et al. 2004; Schäfer-Keller, Steiger, 
Bock, Denhaerynck, & De Geest, 2008).   A recent study exploring the diagnostic accuracy of 





information obtained from patient self-report and/or clinician collateral reports, and/or 
nontherapeutic assay results as having the highest sensitivity to nonadherence (72.1%) (Schäfer-
Keller, et al. 2008).  While specificity of the same composite score was low, evidence supports 
continued use of the composite score as a screening measure.  Given the identified limitations 
associated with current methods of measurement, the continued use of measures of self-report as 
one component of assessing subclinical nonadherence is supported. 
Prevalence and Outcomes of Nonadherence 
 
Variations in definition and measurement prevent accurate representation of both the 
prevalence of IST nonadherence and the effect of IST nonadherence on clinical outcomes.  The 
majority of studies attempt to demonstrate the effect of IST nonadherence on the clinical 
outcomes of acute and/or late rejection and graft failure and/or loss.  A few isolated studies 
focusing on economic outcomes have explored with impact of IST nonadherence on healthcare 
costs. 
Advances in immunosuppression have reduced the incidence of acute rejection episodes 
in the first year following transplantation (Denhaerynck et al. 2009).  Despite the decrease in 
acute rejection rates, significant improvements have not occurred in long-term graft survival 
(Meier-Kriesche, Schold, Srinivas, & Kaplan, 2004).  Early allograft damage, attributed to 
episodes of acute rejection, contributes to the development of chronic allograft nephropathy 
(chronic rejection) (Pascual, Theruvath, Kawai, Tolkoff-Rubin, & Cosimi, 2002).  Acute 
(occurring within the first year) and late acute rejection episodes (occurring > 1 year from 





been found to be strongly associated with late graft loss (De Geest et al. 1995; Joseph et al. 2001; 
Sijpkens, Doxiadis, Mallat, Fijter, & Bruijn, 2003; Nevins & Thomas, 2009).  In renal transplant 
recipients with ten years of graft function, allograft nephropathy (chronic rejection) was one of 
the identified causes of most graft loss (Matas, Gillingham, Humar, Kandaswaym, Sutherland, 
Payne, Dunn, & Najarian, 2008). 
While the majority of prospective studies exploring IST nonadherence identified higher 
rates of acute rejection, graft loss, graft failure, and greater association with late acute rejection 
episodes in recipients identified as nonadherent (Morrissey et al., 2005; Nevins & Thomas, 2009; 
Brown et al. 2009; Nevins, Kruse, Skeans, & Thomas, 2001; Pinkey et al. 2009; Vlaminck et al. 
2004; Hilbrands, Hoitsma, & Koene, 1995), two recent studies yielded conflicting results.  A 
retrospective cohort study conducted by Denhaerynck and colleagues (2009) reported no 
association between nonadherence and graft failure / graft function in a sample of renal 
transplant recipients at least one year from transplant followed over a five year period.  One 
study limitation identified by the researchers as contributing to these conflicting results was the 
exceptionally high rate of adherence (98.4%) that might have exceeded the threshold necessary 
to detect the effect of nonadherence.  Other noteworthy research processes involved in the study 
included an adherence enhancing intervention carried out in nonadherent patients immediately 
following baseline measurement.  In addition, the authors concluded that the use of newer, less 
nephrotoxic IST medications taken by 62% of the sample (mycophenolate mofetil, tacrolimus, 
sirolimus) may have reduced the detrimental effects of nonadherence on long-term renal function 
resulting in the inability to determine the mediating effects of nonadherence in the relationship 





recipients from 8 transplant centers conducted by Israni and colleagues (2011) followed 
participants 18 years of age and older who were recruited at the time of transplant and followed--
up with telephone interviews after discharge and every six months for 36 months.  Medication 
adherence was measured using electronic cap monitoring systems (eDEM© cap) during the 
initial 6 months posttransplant.  While acute rejection occurred in 10% (n =25) of the sample, 
adherence was not associated with acute rejection or decline in glomerular filtration rate (Israni 
et al., 2011).  Possibly contributing to the lack of association between adherence and outcomes in 
this study were two factors:  1)  the limited time monitoring adherence potentially not 
representing adherence patterns during the remaining study period, and 2) electronic monitoring 
may have introduced measurement error by underestimating the amount of nonadherence 
(inability to prove ingestion) (Israni et al. 2011). 
Studies exploring the economic outcomes associated with IST nonadherence are limited.  
Given that 36.4% of graft failures that occur within the first year following transplant result from 
IST nonadherence, $100 million in additional healthcare costs can be attributed to first year graft 
failures (Hansen, Seifeldin, & Noe, 2007).  In addition, assuming 53% of rejection episodes were 
likely attributed to IST nonadherence, $13-$16 million dollars was necessary to treat and prevent 
graft loss (Hansen, Seifeldin, & Noe, 2007).  More recent studies by Pinsky and colleagues 
(2009) and Evans and colleagues (2010) identified cost-related outcomes associated with 
nonadherence.  Pinksy et al. (2009) in a survey of 254 U.S. renal transplant programs reported 
68% of programs reported deaths and graft loss associated with cost-related IST medication 





transplant recipients with Medicare coverage through the first year identified a $12,840.00 
increase in individual three year healthcare costs in recipients with persistently low adherence. 
Determinants of Nonadherence 
 
Five categories of interrelated risk factors, reflective of the World Health Organization’s 
(2003) categories, have been identified as influential to IST nonadherence in adult renal 
transplant recipients:  1) socioeconomic, 2) patient-related, 3) condition -related, 4) therapy -
related, and 5) healthcare system / healthcare provider- related factors. 
Socioeconomic-Related Variables  
  
Socioeconomic factors, while relatively nonmodifiable in nature, have been the most 
widely studied factors within the adult renal transplant population.  Consistent with global 
studies exploring predictive values of these factors (age, gender, race, income level, education) 
across illness categories (World Health Organization [WHO], 2003), results have been 
inconsistent within the adult renal transplant population.  Similar to the multiple conceptual and 
operational definitions of adherence, multiple representations of socioeconomic variables within 
the adult renal transplant population (age, education, race, income level) may possibly contribute 
to the inconsistent findings.   
The majority of studies conducted within the adult population consistently conclude 
younger age as being associated with nonadherence (Chisholm et al. 2005; Chisholm, 
Williamson, Goldfarb-Rumyantzev, Wright, Ragasa, Ostler, Van Orden,  et al. 2011; Lance, & 
Mulloy, 2007; Denhaerynck et al. 2007; Frazier et al. 1994; Ghods et al. 2003; Greenstein & 





al. (2005) suggested that studies failing to associate a younger age with nonadherence lacked a 
significant subsample of adolescents.  The authors hypothesized that without a representative 
sample of adolescents, adherence might remain stable over the lifespan as long as cognition 
remained intact (Denhaerynck et al. 2005).  Contrary to these studies, two recent studies reported 
findings that indicate nonadherence increases with age.  In a study by Chisholm et al. (2008) 
results of the study found nonadherence increased as age increased.  The second study identified 
86% of the study population consisting of adults age 55 and older (mean sample age of 60.38 
years) as being nonadherent with medications (Russell, Centingok, Hamburger, Owens, 
Thompson  et al., 2010). 
 A few isolated studies have attempted to delineate age ranges of both younger and older 
recipients.  Schwizer, Rovelli, Palmeri, Vossler, Hull, and Bartus (1990) differentiated between 
younger (< 20 years) and older (> 40 years) in age as reported in years, while Greenstein and 
Seigel (1998) reported older (mean age 47.9 years) and younger (mean age 41.1 years) recipients 
in terms of mean ages.  Nevins, Kruse, Skeans, and Thomas (2001) defined “young” as < 21 
years of age.  A 1999 study comparing symptom frequency and distress in patients delineated 40 
years of age as the median age separating older from younger patients (Teixeira De Barros & 
Cabrita, 1999).   Chisholm-Burns and colleagues (2008) concluded that older recipients (those 60 
years of age and older) were more likely to be nonadherent than younger recipients (those 
between age 18-60 years of age).    
Variations exist in the operationalization of education with studies delineating low versus 
high levels of education; elementary, high school, and college; while others delineate education 





with adherence yielded similar conflicting results with no consistent association with IST 
nonadherence identified (Goldfarb-Rumyantzev et al. 2011; Butler et al. 2004; De Geest et al. 
1995; Frazier et al. 1994; Ghods et al. 2003; Greenstein & Siegal, 1998; Raiz et al. 1999; 
Vasquez et al. 2003).   
 Studies exploring both race and income level have yielded mixed results making 
determination of a consistent relationship with IST adherence difficult (see Table 3).  Multiple 
operational definitions of race evident in the current body of knowledge include: 1) whites, 
nonwhites; 2) black, 3) Caucasian, African American, Hispanic, and 4) black, nonblack.  
Socioeconomic status operationalized in terms of income level (mean annual income level), 
socioeconomic class (low, middle, high), and employment status (part-time, full-time, 
unemployed, student, retired; white collar, blue collar occupation) equally contribute to mixed 
results. 
Patient-Related Variables  
 
Of greater interest to clinicians are the modifiable patient-related or condition-related 
factors influencing the origins of IST adherence behavior.  Health beliefs, conceptualized as the 
personal convictions that influence health behaviors (Moorhead, Johnson, Maas, & Swanson, 
2008), encompass a combination of attitudes that include the perceived susceptibility of 
experiencing a harmful condition, the perceived seriousness of a condition, the perceived benefit 
the performance of the health behavior has in reducing the threat of the condition, and perceived 
barriers related to the negative aspects of a health behavior (Champion, 1984).  A perceived need 





(Butler et al., 2004; De Geest et al., 1995; Greenstein, & Siegal, 2000; Greenstein & Siegal, 
1998; Raiz et al. 1999).  
Qualitative studies support findings obtained through quantitative methods with regards 
to health beliefs.  A phenomenological study by Orr et al. (2007) of 26 adult renal transplant 
recipients identified the theme of health beliefs as one of four patient perceived factors that 
influence IST medication adherence. 
Research examining the effect of social interactions (social networks, social support) on 
IST adherence is limited.  Social network variables such as living alone and/or being unmarried 
have been found to be associated with nonadherence (Butler et al. 2004; De Geest et al. 1995; 
Frazier et al. 1994; Raiz et al. 1999; Teixeira de Barros & Cabrita, 2000).  Social support, 
defined as the existence or availability of a person or network of people that rely, care, and love 
an individual and on whom that same individual can rely (Sarason, Levine, Basham, & Sarason, 
1983) is categorized as both perceived social support (individual’s perception of available 
support) and received social support (support actually received by an individual) (Dobbels, 
Verleden, Vanhaecke, & DeGeest, 2006).  Additional dimensions of social support identified in 
the literature include:  1) source of support, 2) satisfaction of support, and 3) type of support 
(emotional, instrumental or practical, informational, affirmational) (Chisholm-Burns, Spivey, & 
Wilks, 2010).   The effect of social support on IST adherence among organ transplant recipients 
varies across studies.  A meta-analysis by Dew et al. (2007) found poorer social support in solid 
organ transplants (kidney, heart, liver, pancreas, kidney/pancreas and heart and lung) to be 
associated with significantly greater IST nonadherence though the effect size was weak.  While 





social functioning as associated with adherence, additional study results are inconsistent 
(Greenstein & Siegal, 2000).  Kiley et al. (1993) identified nonadherence in renal transplant 
recipients to be associated with perceived amount of social support, while at the same time 
Frazier et al. (1994) found no relationship between social support and adherence.  By contrast, a 
recent study conducted by Chisholm-Burns et al. (2010) identified a significant positive 
relationship between two types of social support (affectionate and instrumental  
support) and IST adherence.   
Additional research into the contribution of the categories and dimensions of social 
support on long-term IST adherence is warranted due to the changing nature of both the scope of 
healthcare services and social support networks as time from transplant increases.   
Condition-Related Variables 
 
Symptom experience can be conceptualized as both symptom occurrence and symptom 
distress (Kugler, Geyer, Gottlieb, Simon, Haverich, & Dracup, 2009).    Representing the 
cognitive component of symptom experience, symptom occurrence can be quantified by the 
frequency, severity, and duration of a given symptom, while symptom distress captures the 
emotional burden association with the symptom (Kugler et al. 2009).  Though most often 
investigated within the context of its effect on quality of life, symptom experience (symptom 
occurrence / symptom distress), noted to be associated with an increased risk for nonadherence 
in early studies (Butler et al. 2004; Denhaerynck et al. 2007; De Geest et al. 1995; Greenstein & 
Seigel, 1998; Sketris et al. 1994; Teixeira de Barros & Cabrita, 1999).  Symptom experience has 





not within the context of adherence research but rather as a method of evaluating symptom 
profiles associated with immunosuppressant therapy (Koller, Denhaerynck, Moons, Steiger, 
Bock, & De Geest, 2010).  In light of evolving immunosuppressant regimens, quantitative 
exploration of the effect of symptom experience on adherence is warranted.    
 Therapy-Related Variables  
 
A variety of independent variables categorized as therapy-related variables have been 
explored in previous IST adherence studies.  With the typical cost of IST therapy alone 
exceeding $10,000 annually, a few isolated studies have explored the effect of cost on IST 
adherence.   Despite receiving medications free of charge, two studies concluded IST adherence 
to decrease over time suggesting drug cost alone as not influencing adherence (Chisholm et al. 
2005; Chisholm et al. 2000).   
Across the majority of studies, increased time from transplant, conceptualized as months, 
years, and mean years/months since initial transplant, has demonstrated association with 
nonadherence (Chisholm-Burns et al. 2008; Chisholm et al. 2005; Chisholm et al. 2000; 
Greenstein & Seigel, 2000; Greenstein & Seigel, 1998; Hardstaff, Green, & Talbot, 2003; 
Nevins, Kruse, Skeans, & Thomas, 2001; Nevins & Thomas, 2009; Sketris et al. 1994; Vasquez 
et al. 2003).  Additional findings by Chisholm-Burns et al. (2008) identified a trend toward 
higher adherence rates in recipients four years or less posttransplant indicating a possible need 
for the implementation of interventions to support adherence as patients approach four to five 





Across chronic illness categories, complex dose regimens have been found to contribute 
to poor medication adherence.  In a systematic review of 76 studies encompassing a variety of 
disorders using electronic monitoring as the measure of adherence, researchers concluded mean 
dose-taking adherence declined as the number of daily doses increased (Claxton, Cramer, & 
Pierce, 2001).  Adherence was significantly higher in once-daily dosing regimens versus three 
and four times daily regimens (Claxton et al., 2001). 
Studies conducted within the transplant population have yielded similar results.  In a 
study of 182 renal transplant recipients taking cyclosporine as a component of either dual or 
triple IST therapy, Sketric and colleagues (1994) noted the number of overall prescription 
medications significantly affected adherence.   A later study, exploring adherence in a sample of 
278 adult recipients recruited at the time of transplant and followed during the first year, 
identified a significant association between once daily versus twice daily dosing frequencies 
(Weng et al., 2005).  Studies exploring the impact of medications prescribed to manage 
comorbid conditions in addition to IST medications noted similar results (Vasquez, et al. 2003; 
Goldfarb et al. 2009).   
Efforts to improve IST medication adherence have led to the development of a reliable, 
prolonged formulation of tacrolimus (Advograft).  Available since 2007, the more convenient 
once daily dosing regimen was preferred by 99.4% of a sample (n=1832) of European adult renal 
transplant recipients undergoing conversion from twice-daily to once-daily dosing with 
tacrolimus (Guirado, Cantarell, Franco, Huertas, Fructuoso, et al. 2011).  Thirty-four percent of 





any deviations from dose schedule.  Increased adherence was postulated to be due to increased 
convenience of not have an evening medication dose (Guirado et al. 2011). 
 Healthcare System-Related Variables 
 
The influence of the healthcare system has been explored in two studies.  Denhaerynck 
and colleagues (2006) compared IST adherence rates of American and European renal transplant 
recipients failing to identify specific healthcare system factors at the micro or macro level as 
significantly influencing nonadherence.  An additional study conducted by Weng et al. (2005) 
identified transplant center characteristics as independently associated with adherence noting that 
the center may serve as a proxy for characteristics that promote adherence (cultural competency, 
staffing levels, frequency and quality of contact with providers, effectiveness of education).  A 
recent study explored the effect of primary insurance on the risk of nonadherence (Chisholm et 
al. 2007).  Researchers concluded that recipients with Medicare coverage were significantly less 
likely to be nonadherent to IST medications compared to those recipients who did not have 
Medicare coverage (Chisholm et al. 2007).  A variety of private and government (Medicare, 
Medicaid) payor options are available to individuals undergoing renal transplantation with 
varying conditions of coverage.  Medicare is the primary payor for approximately 70% of renal 
transplant recipients and a secondary payor for others (Woodward, Schnitzler, Lowell, 
Spitznagel, & Brennan, 2001).  For patients eligible for Medicare coverage at the time of their 
transplant due to age, disability or entitlement secondary to end stage renal disease, Medicare 
pays 80% of costs associated with IST therapy (Cleemput, Kesteloot, Vanrenterghem, & De 





due to end stage renal disease entitlement losing coverage after 36 months.  Though a study 
conducted by Yen and colleagues (2004) concluded extending Medicare Coverage of IST 
therapy for the life of a kidney transplant would result in both improved graft survival rates and 
significant cost savings to society, only a single isolated study has explored the association of 
payor type with nonadherence.  With over 15,000 transplant recipients securing Medicare 
benefits by entitlement (U.S. Renal Data Systems, 2009), coupled with the increased interest in 
preemptive transplantation as a strategy to improve outcomes, the potential for an increase in the 
number of individuals with limited IST coverage warrants further exploration as a risk factor for 
nonadherence. 
 While research has identified several variables influential to IST adherence, to date, no 
study to date has focused on predictor variables that significantly influence IST adherence in a 
population of long-term (3 years or more from transplant) renal transplant recipients.  Given the 
effect of nonadherence on graft outcomes and the influence of increased time since transplant on 
IST adherence, further exploration and identification of influencing factors in long-term adult 
renal transplant recipients is warranted if long-term outcomes are to improve.    
Framework 
 
 Guiding the conduct of this study is the Health Decision Model, a third generation 
representation of the Health Belief Model proposed by Eraker, Kirscht, and Becker (1984).  
Within the context of adherence, the Health Belief Model (Becker, 1974) attributes the 
probability of adherence behavior to the interaction among an individual’s perception of illness 





encountered with a prescribed intervention.  The Health Decision Model focuses on health 
decisions and the influence of patient preferences, health beliefs, and modifying factors on an 
individual’s adoption of a health behavior (see Figure 1). 
 The ability of an individual to express preferences that influence health decisions has 
been associated with both decision analysis and behavioral decision theory (Eraker & Politser, 
1982).  Decision analysis provides a systematic process whereby individuals express preferences 
about risks and benefits associated with a therapeutic action.  Behavioral decision theory extends 
decision analysis by identifying rules used by individuals to reduce complex decisions into 
simple ones (Eraker & Politser, 1982).  Ultimately, the preferred course of action adopted by the 
individual reflects the outcome that offers the highest value.   
 Health beliefs and several categories of modifying factors identified as components of the 
Health Decision Model are congruent with variables identified as contributing to adherence 
within the adult renal transplant population. Variables to be explored in this study, reflective of 
categories represented in the Health Decision Model include:  1) specific health beliefs regarding 
the necessity of prescribed medications as quantified by the Beliefs About Medicines 
Questionnaire, 2) symptom experience associated with the prescribed IST regimen as quantified 
by the Modified Transplant Symptom Distress/Symptom Occurrence scale, 3) social support as 
quantified by the Modified Social Support Survey, and 4) demographic variables categorized 
consistent with the Organ Transplant and Procurement Network national database (2012) as 
available.  As illustrated by the bidirectional arrows and feedback loops depicted in the Health 
Decision Model, adherence behavior can also change health beliefs.  In addition, while the 





will seek to identify which combination of variables best predicts the probability of adherence 
behavior in the sample population. 
 Lacking in the current representation of health decisions and health behavior adherence 
(see Figure 1) are both the dimensions of medication taking adherence (taking, timing, omitting/ 
drug holiday, dose reduction)  and the profiles of nonadherent individuals (accidental, 
invulnerable, decisive) identified in seminal work conducted by Greenstein and Siegal (1998).   
Representation of adherence dimensions will be captured through use of the self-report Basel 
Assessment of Adherence to Immunosuppressive Medication Scale (BAASIS) and examination 
of specific beliefs regarding IST medications using the Beliefs about Medicines questionnaire.  
Three areas represented in the model will not be explored in this study.  First, health 
outcomes associated with adherence behaviors including acute rejection, late acute rejection, and 
graft failure will not be explored within the context of this study as examination of these 
outcomes exceeds the proposed study purpose and design.  Second, health decisions, or the 
process by which individuals make decisions that influence adherence will not be explored in 
this study.  The decision to undergo transplantation as a treatment for end stage renal disease 
involves a decision making process that includes evaluating the lifelong therapy necessary to 
sustain the transplant.  Given the long-term posttransplant sample population selected for study, 
key decisions related to adherence behaviors are assumed to have already occurred.  Lastly, 
knowledge as it relates to IST interventions will not be explored.  It was a study assumption that 
long-term participants would already possess the necessary knowledge regarding IST 






Figure 1 depicts adaptations to the Health Decision Model reflective of this study.  Figure 
2 illustrates the adapted model that served as a guide for this study. 
 
Adapted from “Understanding and Improving Patient Compliance”  by Stephen A. Eraker and John P. Kirscht,  
1984, Annals of Internal Medicine, 100, p.261 
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This chapter has presented the current state of the knowledge regarding 
immunosuppressant adherence in renal transplant recipients, issues with definition and 
measurement, and variables that impact optimum IST adherence.  Strengths of the literature 
review are that much research has been conducted on IST adherence in renal transplant recipients 
since the early 1990’s.  Studies exploring the impact of nonadherence on acute and late acute 
rejection and graft loss have noted the influence on outcomes and propelled further research 
studies focused on identifying contributing factors.  Additional studies exploring the impact of 
categories of influencing factors (socioeconomic, patient-related, condition-related, therapy 
related, and healthcare system / healthcare team-related factors) have led to predictive models 
and profiles that have identified variables amenable to intervention. 
 While strengths in the literature review were evident, weaknesses emerged.  Given the 
focus on improving long-term outcomes, no study was identified that focused on exploring 
contributing factors in a population of long-term recipients.  While many study populations 
included recipients that were several years from transplant, many studies included recipients as 
early as six months from transplant.  In addition, immunosuppressive regimens have evolved 
over time potentially altering the symptom experience and complexity of dosing regimens.  
Finally, given the continued evidence surrounding the limitations of all methods of measuring 
medication adherence, only a few studies have explored the phenomenon using a combination of 
methods suggested to better represent the prevalence of adherence.  This research study will add 
to the current state of knowledge by exploring factors known to influence IST adherence in a 





known to influence adherence in previous studies are the same or different in long-term 
recipients.  Findings could identify modifiable factors amenable to interventions that could 







CHAPTER THREE:  METHODS 
 
The purpose of this study was to examine demographic variables, time since transplant, 
immunosuppressive agents, health beliefs, symptom experience, and social support and test their 
effect on IST adherence in a population of long-term adult renal transplants as predicted by the 
Health Decision Model (Eraker, Kirscht, & Becker, 1984). 
Design 
 
  A cross-sectional, correlational design was used in this study to collect data at a single 
point in time using a voluntary convenience sample.  This design was chosen to understand the 
relationships between the predictor variables of demographics, time since transplant, 
immunosuppressive agents, health beliefs, self-efficacy, symptom experience and social support 
and test their effect on the outcome variable of IST adherence in adult renal transplant recipients.  
 Sample 
 
 The study population consisted of a convenience sample of eligible adult renal transplant 
recipients who were three years or more from transplant and due to attend their annual transplant 
clinic appointment.  The sample was obtained from patients receiving care at a large transplant 
center that met inclusion criteria and gave consent.  Demographic data obtained at enrollment 







 Inclusion/Exclusion Criteria 
 
 To be included in the proposed study, sample participants must have been > 21 years of 
age at the time of initial transplant; single kidney transplant recipient; able to speak, read, and 
understand the English language; had a functioning graft at the time of the study; and be three 
years or more from initial transplant.  Graft function was determined by measured serum 
creatinine levels.  A serum creatinine of 0.6-1.2 mg / dL from the clinic laboratory was 
considered normal range.  Serum creatinine values obtained from outside laboratories were 
evaluated using reference values established by the transplant clinic laboratory.  Transplant 
recipients with elevated serum creatinine levels were included in the study if the level was within 
the patient’s maintenance baseline as determined by the transplant clinic provider.   
Participants were excluded from the study if the elevated serum creatinine was not within 
the patient’s maintenance baseline or if the participant had been retransplanted.  Due to a lack of 
studies validating instruments in languages other than English, participants that did not speak, 
read or understand the English language were excluded from the study. 
Determination of Sample Size 
Power Analysis 
An a priori power analysis was calculated by means of G*Power 3.0.8 (Faul, Erdfelder, 
Lang & Bucher, 2007) to determine the required sample size given a level of significance (α = 
.05), power of .80 (β = 0.20) and medium effect size (0.15) for linear multiple regression.  Effect 






 The primary research question contained six independent variables which were examined 
for relationships to the outcome variable of IST adherence.  Statistical analyses planned included 
chi-square, Spearman correlation, independent-samples t test, and logistic regression.  For 
logistic regression analysis with six predictor variables, anticipating a medium effect size (0.15), 
a sample of 98 was necessary.  The sample size of 98 was further supported with 
recommendations for a ratio of subjects to independent variables of at least 15 :1 (Mertler & 
Vanatta, 2005; Tabachnick & Fidell, 2007), which was a minimum of 90 subjects.   
Setting 
 
The site selected for the conduct of this study was Florida Hospital Transplant Clinic, a 
single site outpatient transplant clinic, in operation since 1973 and located in a large urban 
community in the Southeastern region of the United States.  Since 1988, a total of 2,686 kidney 
transplants (living related-567; deceased donor-2119), procedures were performed across ethnic 
categories (White, Black, Hispanic, Asian, American Indian/Alaska Native, Pacific Islander, 
Multiracial) in the acute care facility associated with the outpatient clinic (Organ Procurement 
Transplant Network [OPTN], 2011).  The site was selected due to the length of time in operation, 
the size of the recipient database, the scope of transplant services provided by the clinic, and the 
potential representation of the sample population. 
 Following completion of the acute care phase after renal transplantation provided by the 
Florida Hospital Transplant Clinic, primary care of the transplant recipient shifted to the local 
nephrologist for long-term care.  Long-term follow-up care included monthly visits with the 





In addition to care provided by the local nephrologist, Florida Hospital Transplant Clinic 
followed the patient every 6 months during the first year posttransplant and annually thereafter.  
Immunosuppressive agents prescribed by providers at the clinic included tacrolimus (Prograf), 
sirolimus (Rapamune), cyclosporine (Neoral), mycophenolate mofetil (Cellcept), mycophenolate 
sodium (Myfortic), and prednisone.  The primary IST regimen used included tacrolimus 
(Prograf) in combination with either mycophenolate mofetil (Cellcept) or mycophenolate sodium 
(Myfortic) with or without prednisone. If prednisone was a part of the IST regimen at 6 months 
posttransplant, doses were reduced monthly to a final dose of 5 mg/ day.  Therapeutic monitoring 
of IST regimens included serum trough levels of tacrolimus (Prograf)  and/or sirolimus 
(Rapamune) drawn within one week of the recipient’s scheduled appointment if drawn at an 
outside lab or the day of the appointment if drawn at the Transplant Clinic lab.  Therapeutic drug 
monitoring of mycophenolate mofetil (CellCept) and mycophenolate sodium (Myfortic) was not 
performed at this site.  Dosage adjustments of Cellcept and/or Myfortic occurred only in the 
presence of adverse clinic effects (persistent, severe diarrhea, severe leukopenia < 2.0) and after 
consultation with clinic providers. 
Approximately 30-45 patients were seen monthly for annual transplant follow-up 
evaluation.   It was estimated that 10 patients per month would meet study inclusion criteria.  
The data collection period began July 2010 and concluded September 2011 with a total of 98 





















*Missed = cancelled appointment, no-show for scheduled appointment, or missed by PI 
Figure 3:  Enrollment Summary  




103 Consented participants 
5 Did not meet final inclusion criteria 
98 Met final inclusion criteria 
98 Enrolled 







Protection of Human Subjects 
 
Protection of study participants was accomplished by adhering to ethical and legal 
guidelines. All policies for protection of human subjects mandated by the institutional review 
boards of the University of Central Florida and Florida Hospital, and United States Federal 
Guidelines for conducting research with human subjects (U.S. Department of Health and Human 
Services (DHHS), 2001) were followed.  Authorization to access individually identifiable health 
information was accomplished by having study participants sign a HIPAA Privacy Authorization 
form which was part of the informed consent process.  
Informing Participants 
 
The study was approved by the Institutional Review Boards of both Florida Hospital and 
the University of Central Florida (see Appendix H).  Informed consent was obtained by the 
principal investigator.   
Protecting Respondents 
 
Individual responses to study instruments were anonymous; no identifying information, 
such as name or address was collected.  Confidentiality was accomplished by assigning each 
participant a five digit study identification number which eliminated the discovery of any 
personal information. The created identification number was not linked to any personal medical 





her research supervisor had access to the data files which were stored in a password protected 
computer. 
Risks and Benefits to Participants 
 
While there were no anticipated risks involved in participating it was possible that a 
participant could experience minor psychological discomfort when disclosing both symptom 
experiences as well as adherence behaviors. There were no direct benefits to participants aside 






Recruitment of participants was facilitated through use of the transplant center’s recipient 
database.  The transplant clinic coordinator in charge of scheduling annual follow-up 
appointments provided a weekly list of the number of potential participants meeting initial study 
inclusion criteria (age> 21, single transplant, and 3 or more years from initial transplant) to the 
principal investigator.   The list provided to the principal investigator included only the date and 
time of the potential participant’s annual clinic appointment. Initial interest in study participation 
was determined upon arrival of the potential participant for the annual visit and was facilitated 
by clinic staff.  Recipients expressing an initial interest in study participation were approached 
by the principal investigator to obtain informed consent, and then screened for final study 





advertising the study was posted in the transplant clinic waiting room (see Appendix A).  At 
month 12, initial study inclusion criteria was amended to exclude eligible participants previously 
enrolled in this study during the past year to avoid studying the same subjects twice. 
Data Collection Process 
 
Data collection was conducted by the principal investigator who was unknown to study 
participants and was not a member of the outpatient transplant clinic staff.  Medical data (serum 
creatinine levels and serum drug assays) were obtained through a review of each participant’s 
medical record conducted following the informed consent process.  Medical data reviewed 
included serum creatinine and serum drug assay results as reported on the day of the participant’s 
evaluation. The majority of participants had lab drawn in the clinic lab, a Clinical Laboratory 
Improvement Amendments (CLIA) certified lab.  For participants with insurance designated 
requirements to use independent selected labs, only specimens drawn within the week prior to 
the annual clinic appointment were accepted. 
All study instruments were administered by the principal investigator using an interview 
format in the private examination room located within the outpatient transplant clinic.  The 
average wait time for clinic appointments was approximately 30-60 minutes for patients 
requiring laboratory services, and 15-30 minutes for patients not requiring laboratory services.  
Based on the identified time intervals, all potential participants underwent final screening and 
consenting immediately prior to their clinic appointment.  If time permitted, all study instruments 
were administered prior the participant’s medical visit. Participants were presented study 





Questionnaire (BMQ) (Horne, Weinman, & Hankins, 1999), 3) the Medical Outcomes Study 
(MOS) Modified Social Support Survey (MSSS) (Ritvo, Fischer, Miller, Andrews, Paty, & 
LaRocca, 1997), 4) the Basel Assessment of Adherence with Immunosuppressive Medication 
Scales (BAASIS) (De Geest, 2005), and 5) the Modified Transplant Symptom Occurrence and 
Symptom Distress Scale-59R (MTSOSD-59R) (Dobbels, Moons, Abraham, Larsen, Dupont, & 
De Geest, 2008).  All instruments were administered in computer format using Survey 
Monkey™ (http://www.surveymonkey.com/).  Use of the computerized methods for data 
collection were piloted with the first 5 subjects who found it acceptable.  In addition to the 
instruments completed by study participants, a collateral assessment of adherence was completed 
by one transplant clinic registered nurse and the attending transplant clinic physician or nurse 
practitioner at the conclusion of the participant’s examination.  
In the event the participant declined use of the computer, or was unable to operate a 
computer, paper instruments were made available to the participant.  Data obtained from paper 
instruments were entered into the Survey Monkey™ file by the principal investigator, with each 
survey item double checked for accuracy. 
Approximately one hour was allotted during the participant’s clinic appointment for 
instrument completion.  All instruments completed on paper were examined for missing items 
prior to the participant leaving the study session.  Participants were compensated with a $25.00 








Data Collection Procedures 
 
All  study data recorded in the Survey Monkey™ program was downloaded by the 
principal investigator into a Microsoft Excel spreadsheet, and imported into the Statistical 
Package for the Social Sciences (SPSS) for Windows v 19.0 (SPSS, Inc., 2010) for statistical 
analysis. No errors in data entry were identified.   Figure 4 summarizes study data collection 
























Figure 4:  Data Collection Processes and Procedures 
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Access to study data was limited to the principal investigator and the chair of her 
dissertation committee. Once downloaded to the principal investigator’s password protected 
computer, all data were backed up onto a compact disk (CD) and stored in a locked file cabinet 
in the principal investigator’s office.  At the end of a five year time frame, the CD and any other 
research materials will be destroyed. 
Pilot Study 
 
A pilot study was conducted on the first 5 participants for the following purposes:  1) 
testing the feasibility of study instruments, 2) determining clarity of instrument instructions, 3) 
obtaining an average estimation of instrument completion time, and 4) evaluating potential for 
interruptions in transplant clinic work flow.   Data obtained from pilot study participants were 
included in the analysis as no instrument modifications were made.  One minor modification was 
made to the study protocol allowing for administration of all study instruments prior to the 
participant’s clinic appointment if time allowed.   
Instrumentation 
 
In addition to demographic information, participants completed the following data 
collection instruments:  1) Beliefs About Medicines Questionnaire (BMQ); 2) Medical Outcomes 
Study (MOS) Modified Social Support Scale (MSSS), 3) Basel Assessment of Adherence with 
Immunosuppressive Medication Scale (BAASIS), and 4) the Modified Transplant Symptom 





these measures demonstrated reliability and or validity either within the adult renal transplant or 
chronic illness populations.  In addition, all measures had the same recall period of four weeks to 
reduce the potential for recall bias.  Measures not evaluated previously evaluated within the adult 




Demographic variables were collected using both participant and investigator collected 
instruments developed specifically for the study.  All participant demographic variables were 
defined using categories as delineated by the Organ Procurement Transplant Network (2011) 
and/or the United States Census Bureau (2010). 
 Select demographic variables were calculated:  age, time postttransplant, and the IST 
medication complexity index.  Age at the time of study and time posttransplant were calculated 
and reported in years using birthdate, transplant date, and date of enrollment.  Complexity of IST 
regimen was represented by a complexity index score calculated as the product of the number of 
IST medications in the regimen, the number of pills taken per day, and the number of times per 
day IST medications were taken. 
 Serum creatinine, as reported the day of enrollment, was obtained from the medical 
record.  Serum creatinine values from all laboratory sources were evaluated using transplant 
clinic normal values (0.6-1.2 mg / dL) consistent with provider practice.  
Serum drug assays were evaluated according to target therapeutic values determined by 





include:  tacrolimus:  5-10 mg/L; sirolimus:  8-15 mg/L; and cyclosporine 150-250 mg/L.  
Therapeutic monitoring for mycophenolate mofetil (CellCept) and mycophenolate sodium 
(Myfortic) was not conducted at this facility.   
Beliefs About Medicines Questionnaire 
 
 The Beliefs about Medicines Questionnaire (BMQ) constructed and tested by Horne, 
Weinman, and Hankins (1999) is composed of two sections:  BMQ Specific and BMQ General.  
The BMQ Specific is further divided into two five-item subscales:  Specific Necessity assessing a 
patient’s beliefs about the necessity of prescribed medications, and the Specific Concerns 
assessing concerns about consequences of taking the same medications.  The BMQ General 
section, which include the General Harms subscale and General Overuse subscale, assesses 
beliefs held by patients that often seek alternative methods of treatment such as herbal treatments 
or care from a homeopathic clinic (Horne et al., 1999).  This section of the instrument was not 
applicable to the population under study and therefore was not used. 
Validity  
 As part of instrument development, Horne et al (1999) established construct validity of 
instrument scales by performing exploratory principal component analysis.  Scale items were 
derived from a pool of 34 items representing commonly held beliefs identified in the literature 
about medication.  Data were based on a sample of 524 patients encompassing a variety of 
chronic illness categories (asthma n=78, diabetic n=99, renal n=47, psychiatric n=89, cardiac 
n=120, general medical n=91).  Confirmatory factor analysis was conducted to verify the factor 





Specific Necessity subscale and a 0.88 for the BMQ Specific Concerns subscale within the renal 
dialysis subsample. 
 Psychometric evaluation of the instrument provided evidence of both criterion-related 
and discriminant validity (Horne, Weinman, & Hankins, 1999).  Criterion related validity was 
based on a two predictions: 1) that patients with stronger beliefs in the necessity of medication 
would be less likely to believe they can cope without medication (Specific Necessity subscale), 
and 2) that patients with strong concerns about prescribed medication who were more distrustful, 
would require more information about medication and would be more likely to change their 
current treatment regimen (Horne et al, 1999).  Evidence for criterion-related validity was 
demonstrated with a negative correlation between scale scores and responses to the belief that 
they could cope without medicine (Specific Necessity, p<.001)) and a positive correlation 
between scale scores and the belief that they could not always trust medications (Specific 
Concerns, p<.005).   
 Discriminant validity was tested on the ability of the instrument to distinguish between 
different illness and treatment modalities.  Testing hypothesized that beliefs about the necessity 
of medications would be influenced by the type of treatment for a specified illness (Specific 
Necessity) and Specific Concern scores would differentiate between different diagnostic groups 
with concerns varying based upon illness category.  Predictions were confirmed by significantly 
higher Specific Concern scores for identified groups. 
Reliability  
 Cronbach’s alpha values for the renal dialysis diagnostic group established internal 





with the human immunodeficiency virus (HIV) population investigating beliefs associated with 
nonadherence to antiviral therapy identified internal reliability of both BMQ scales with 
Cronbach’s alpha of 0.80 for Specific Necessity, and 0.82 for Specific Concerns (Horne, Buick, 
Fisher, Leake, Cooper, & Weinman, 2004).   
 While the BMQ has been used in a study conducted within the renal transplant population 
(Butler et al., 2004), no additional information specific to the validity and reliability of the 
instrument in the study was provided. 
Scoring 
 Subscale items are measured using a five point Likert scale with one being “strongly 
disagree” and five “strongly agree.”  Possible scores for each subscale range from a minimum of 
five to a maximum of 25, with higher scores indicating stronger beliefs.  A mean score for each 
subscale of the BMQ Specific was calculated by dividing the total scale score by the total 
number of items.  The mean item score for each subscale was used to calculate a necessity-
concerns differential (NCD) which was obtained by subtracting the Specific Concerns mean 
score from the Specific Necessity mean score providing a numerical indicator of the way an 
individual rates the need for medications to concerns over taking medications.  A negative NCD 
value indicated an individual rated concern over taking medications higher than the beliefs about 
the necessity for taking medications.   
Medical Outcomes Study Modified Social Support Scale 
 
 The Medical Outcomes Study (MOS) Modified Social Support Survey (MSSS) is a 





Sherbourne and Stewart (1991).  The 18 item MOS Modified Social Support Scale, one of ten 
subscales modified for use within the Multiple Sclerosis Quality of Life Inventory (MSQLI), 
measures perceived availability of various components of functional support (see Appendix K).  
Within the 18 items are four subscales representing multiple dimensions of social support.  Four 
items (1,4,11,13) measure tangible support, eight items measure emotional/informational support 
(2,3,7,8,12,14,15,17), three items measure affectionate support (5,9,18), and three items measure 
positive social interaction (6,10,16).  A five item version of the MOS MSSS is also available 
(MSSS-5) and consists of the 5 items (items 4, 6, 9, 11, and 17) that correlate most strongly with 
the total MSSS scale with all four subscales represented.  The 18 item instrument was selected 
for use in this study due to the limited number of recent studies exploring social support within 
the renal transplant population. 
Validity 
 Factorial validity, discriminant validity, and construct validity were established for the 
original Medical Outcomes (MOS) Study Social Support Survey by Sherbourne and Stewart 
(1991).  Using responses from 2987 subjects, factor analysis discriminated four dimensions of 
social support:  emotional / informational, tangible, affectionate, and positive social interaction.   
Confirmatory factor analysis of the original 19 items produced high correlations between 
emotional and informational support (0.99) while principal components factor analysis of the 19 
original items show high loadings for all items ranging from 0.67-0.88.  Discriminant validity 
was supported as single-item measures of structural support were distinct from functional 
support concepts.  All items in the four subscales correlated higher with their own scale than 





correlations ranging between 0.72-0.87 for tangible support, 0.80-0.86 for the affection scale, 
0.82-0.90 for the emotional / information scale, and 0.87-0.88 for the positive interaction scale 
(Sherbourne & Stewart, 1991).   
 Confirmatory factory analysis of the original 18-item scale as well as two abbreviated 
versions was performed in a study of 330 mothers with a child in mental health treatment 
(Gjesfjeld, Greeno, & Kim, 2009).  Both the twelve and four item scales demonstrates the best fit 
with reported Goodness of Fit Indices of .95 and1.00 respectively. 
Reliability 
 Sherbourne and Stewart (1991) established internal-consistency reliability of scale scores 
using Cronbach’s alpha.  Pearson Product Moment correlations between support measures at 
enrollment and the same measures one year later estimated one year stability coefficients.  
Analysis performed for the Medical Outcomes Study sample found emotional/ informational 
support, tangible support, positive social interaction, and affectionate support correlations ranged 
between 0.91-.0.96.  One year stability coefficients ranged between .72-.78 across all subscales 
(Sherbourne & Stewart, 1991). 
 The Consortium of Multiple Sclerosis Centers Health Services Research Committee in its 
construction of the Multiple Sclerosis Quality of Life Inventory (National Multiple Sclerosis 
Society, 1997), created the 18 item Modified Social Support Survey as one of 10 subscales used 
to measure health-related quality of life in multiple sclerosis patients.  Analysis yielded 
Cronbach’s alpha for tangible support, emotional support, affective support, and positive 
interaction support ranging between 0.87 and 0.85.  The same Consortium reported a Cronbach’s 





 To date, one study conducted within the adult renal transplant population (Chisholm-
Burns, Spivey, & Wilks, 2009) has used the 5 item version of the MOS-MSSS scale; however 
validity and reliability statistics were not reported.   
Scoring 
 Each of the 18 items are measured on a 5-point Likert scale (1= none of the time to 5= all 
of the time).  The MSSS yields 4 subscale scores (Tangible Support [TAN], Emotional / 
Informational Support [EMI], Affectionate Support [AFF], and Positive Social Interaction 
[POS].  Raw scores range as follows for each subscale:  1) TAN 4-20; 2) EMI 8-40; 3) AFF  3-
15; and 4) POS 3-15.  Higher scale scores indicate greater perceived support. 
Modified Transplant Symptom Occurrence and Symptom Distress Scale 
 
 The Modified Transplant Symptom Occurrence and Symptom Distress Scale (MTSOSD-
59R), was developed as an updated and validated version of the 45 item Modified Transplant 
Symptom Occurrence and Symptom Distress Scale (Moons, De Geest, Versteven, Abraham, 
Vlamick, Moens, & Waer, 2001) to reflect the transplant patient’s symptom experience with 
currently available immunosuppressive regimens (see Appendix K).  The 59 item scale assesses 
symptom frequency and symptom distress associated with the use of current immunosuppressive 
agents (cyclosporine, corticosteroids, azathioprine, tacrolimus, mycophenolic-acid containing 
formulations, mTOR inhibitors and belatacept) (Dobbels et al., 2008). 
Validity 
 To establish content validity, new items generated on the updated scale were added 





belatacept studies, yielding a total of 76 items.  A panel of 21 experts reviewed all items.  Expert 
feedback resulted in the current 59-item version.  Discriminant validity of the scale was tested in 
a pilot study of 24 adult renal transplant patients and 84 lung transplant patients (Dobbels et al., 
2008).  Discriminant validity was supported noting symptom profiles differed significantly with 
females demonstrating a higher symptom occurrence (p =0.096) and significantly higher 
symptom distress (p=0.017).  In addition, patients with depressive symptoms had a significantly 
higher symptom occurrence (P=.030) and higher symptom distress (p=.006) compared to patients 
without depressive symptoms (Dobbels et al. 2008). 
Reliability 
 An earlier study conducted for the purpose of establishing psychometric properties of the 
29 item MTSOSD scale concluded that internal consistency assessment of the scale was neither 
useful or allowed (Moons, De Geest, Versteven, Abraham, Vlamick, Moens, & Waer, 2001).  
This finding was due to the presence of negative correlations in the correlation matrix which 
indicated symptoms were not correlated unidirectionally, violating a key assumption for the 
calculation of Cronbach’s alpha.  As such, internal consistency was not reported in this study. 
 To date, the MTSOSD-59R has been used in one study conducted within the adult renal 
transplant population exploring distress associated with adverse effects of IST medication 
(Koller et al. 2010).  No additional information specific to the validity of the instrument in the 
study was provided.   
Scoring 
 Symptom occurrence and symptom distress are scored on a 5- point Likert scale (0 = 





Each item is a symptom scored in view of both symptom frequency of occurrence and symptom 
distress.  In this study and consistent with previous research, ridit analysis, a statistical method 
used for analysis of ordinal level data (Delesis & Sermeus, 1996), was used to rank symptom 
occurrence and symptom distress items.  Ridit scores range from a minimum of 0 to a maximum 
of 1.  A ridit score of 0.5 represents equal probability, while ridit scores of > 0.5 represents 
higher probability.  For the calculation of individual symptom distress ridits, symptoms reported 
as never occurring were coded as “missing data” and excluded from analysis to be truly 
representative of the symptoms they had.  For final analysis, total individual participant symptom 
occurrence and symptom distress ridit scores were calculated as the sum of all individual item 
ridit values for each scale (symptom occurrence and symptom distress). 
Basel Assessment of Adherence with Immunosuppressive Medication Scale  
 
Developed by the Leuven-Basel Adherence Research Group (2005) to assess recent IST 
adherence (previous 4 weeks) in adult renal transplant recipients, the four item Basel Assessment 
of Adherence with Immunosuppressive Medication Scale (BAASIS) was conceptualized based 
on the dimensions of medication taking adherence (taking, timing, omitting / drug holidays, dose 
reduction).  While there is a measure of IST adherence with demonstrated validity and reliability 
in the adult renal transplant population available (Immunosuppressant Therapy Adherence Scale 
[ITAS]), the BAASIS instrument was used for this study.  Selection of this tool was based on 
more clearly defined scoring categories (0=never to 5=everyday BAASIS; 0%=none to > 50% = 
very frequent ITAS) as well as more recent recall of nonadherence (4 weeks-BAASIS; 3 months-






 Early validation of the instrument has been reported in both the renal transplant 
population as well as the HIV population.  In the adult renal transplant population, all four items 
of the BAASIS scale had superior sensitivity in detecting nonadherence compared with the 
Siegal Scale (Schäfer et al., work in progress of the Leuven-Basel Adherence Research Group).  
A study conducted within the HIV population  demonstrated validity of the scale as a strong 
linear relationship was found between the number of missed doses and optimal viral suppression 
with the test for linear trend highly significant (p < 0.0001) (Glass, De Geest, Weber, Vernazza, 
Rickenbach et al., 2006). 
Reliability 
 Internal consistency, as a measure of reliability of the BAASIS has not yet been 
established within the transplant population.  
To date, the BAASIS instrument has been used in only one study conducted within the 
renal transplant population (Schmid-Mohler et al., 2010).  No information specific to the validity 
and reliability of the instrument in the study was provided.   
Scoring 
 Responses are scored on a 6 point Likert scale (0 = never to 5 = everyday).   For the 
purpose of this study, nonadherence was defined as any self-reported nonadherence (response 
score 1 to 5) on any of the four items.  Consistent with current research (Schmid-Mohler, 2009), 
taking adherence scores were dichotomized as “adherent” (0) and “nonadherent (1-5), and  
timing non-adherence scores were classified ordinally as “adherent” (0), “partial adherent” (1-2) 





Composite Score of Adherence 
 
 Current literature supports the use of a combination of adherence measures to increase 
the diagnostic accuracy of assessing adherence (Schäfer-Keller, Steiger, Bock, Denhaerynck, & 
De Geest, 2008).   
Validity 
 Two composite adherence scores (CAS) were evaluated for validity.  Composite 
adherence score 2 (CAS 2) which consists of a self- report of adherence, collateral reports of 
adherence, and nontherapeutic blood assay viability demonstrated the highest sensitivity 
(72.1%), followed by composite adherence score 1 (CAS1) (62.8%),  validating both as 
acceptable screening measures for IST adherence (Schäfer-Keller et al., 2008).   In the same 
study, validation of the different methods comprising the composite score identified the 
following:  1) non-therapeutic  assay variability and self-reported nonadherence were found to 
correlate significantly (p< .05); 2) self-reported nonadherence correlated significantly with 
measures captured through electronic monitoring methods (p< .05); 3) clinician collateral reports 
significantly correlated with electronic monitoring dosing and taking adherence (p< .05);  4) 
CAS 1 correlated significantly with taking and timing adherence as well as non-therapeutic 
blood assay variability (ranging from r rho = 0.129 [p<.05] to r rho = 0.333 [p<.05]); and 5) CAS 2  
(patient self-reported adherence, clinician collateral report of adherence, and nontherapeutic 
blood assay variability) correlated significantly with electronic monitoring drug holidays , 
dosing, taking, and timing adherence (ranging from r rho =0.135 [p<.05] to r rho =0.289 [p<.05]) 





Composite Score of Adherence Components 
 
BAASIS  
 For use as the self-report component of the final CAS score, a total BAASIS score was 
calculated as the sum of response scores to the four scale items.  Any self-reported nonadherence 
on any of the instruments four items classified the participant as nonadherent.  For final analysis 
as a component of the CAS score, the total BAASIS score was dichotomized (adherent, 
nonadherent), reverse scored, and coded in SPSS as “0”= nonadherent and “1” = adherent. 
Collateral Report of Adherence 
 Collaterally reported adherence, defined as a method of providing information about a 
patient’s medication taking behavior as reported by a third party (De Geest, Abraham, & 
Dunbar-Jacob, 1996),  was measured using two reports:  one provided by the transplant clinic 
registered nurse, and one by the attending transplant clinic provider (physician or nurse 
practitioner) (see Appendix K).  Clinicians were asked to rate the participant’s overall general 
immunosuppressant adherence as “good” (0), “fair” (1), or “poor (2)”.  Consistent with previous 
research (Schmid-Mohler et al., 2009), clinician collateral responses were combined and scored 
as “adherent” (both clinician’s estimated “good”), “partially adherent” (one clinician estimated 
“fair” or “poor”), and “nonadherent” (both clinicians estimated “poor”).  Total combined scores 
ranged from 0-4 (0 = “adherent”, 1-3 “partially adherent”, 4 = “nonadherent”).  For final analysis 
as a component of the composite adherence score (CAS) total collateral report of adherence 
scores were dichotomized (adherent / nonadherent), and coded in SPSS as “0”= nonadherent, and 





Nontherapeutic Blood Assay 
 Serum drug assay was assessed using a single serum trough level for the monitored IST 
agent.  A therapeutic drug range was specified for each immunosuppressive agent based on  
clinical guidelines used at the selected study site.   Therapeutic ranges were defined as  
follows:   tacrolimus (Prograf), 5-10 ng / mL; sirolimus (Rapamune), 8-15 ng / mL; and 
 
cyclosporine (Sandimmune), 15-250 ng /mL.  Mycophenolate mofetil (Cellcept) and 
mycophenolate sodium (Myfortic) therapeutic assays were not currently monitored at the study 
site. Serum drug assays were scored as “adherent” (0) if assessed value was within therapeutic 
range, and “nonadherent” (1) if outside normal range.  For final analysis as a component of the 
composite adherence score (CAS) serum drug assays scores were dichotomized (adherent / 
nonadherent), and coded in SPSS as “0”= nonadherent, and “1” = adherent.   
CAS Scoring  
For final analysis, the composite adherence score (CAS) was calculated and consisted of 
a self-report measure of adherence ( BAASIS), two clinician collateral reports of adherence, and 
a single serum IST medication trough level.  Consistent with the literature, cut-off criteria for 
nonadherence consisted of self-reported nonadherence, and / or at least 1 clinician’s response of 
“fair” or lower adherence, and / or non-therapeutic drug assay (Schäfer-Keller et al., 2008).  The 
sum of the dichotomized scores for the BAASIS, clinician collateral reports, and serum drug 









 Data were analyzed using Statistical Package for the Social Sciences (SPSS; version 
19.0).    All data were prescreened prior to analysis by exploring descriptive statistics, 
characteristics of distribution (central tendency, variability, skewness, kurtosis), and for the 
presence of missing values and outliers. Depending upon the level of measurement and 
distribution of each variable, data were expressed in frequencies or means and standard 
deviations.  Spearman correlation coefficients were calculated to determine the strength of the 
relationship between independent predictor variables and the dependent outcome variable of 
adherence.  Independent-samples t tests were used for two group comparisons of continuous 
variables.  A significance level of < .05 was considered statistically significant. 
To answer the primary research question, logistic regression was performed.  For logistic 
regression, the model fit, classification table, and summary of model variables were evaluated to 
determine the accuracy of the developed regression model. 
Statistical Assumptions 
 Descriptive statistics were computed for all variables.  Data were explored to evaluate 
normality of distribution and homogeneity of variance.  Distributions were evaluated by means 
of histograms, skewness and kurtosis, and the Kolmogorov-Smirnov (D) statistic. Data from 
different participants were independent and not influenced by the behavior of other participants.  
Nonparametric tests were performed for those variables not meeting assumptions of normality 
and for determining the strength of the relationship between variables measured at the ordinal 





were performed to compare means across groups.  Homogeneity of variance was assessed using 
Levene’s test (Mertler & Vanatta, 2005). 
Prior to logistic regression analysis, data were prescreened for outliers, and predictor 
variables were evaluated for multicollinearity.  Goodness-of-fit test was performed to assess the 
fit of the model to the data.   
Quality Control 
 All data were prescreened and evaluated for missing values and outliers.  Missing values 
were minimal and were replaced with the mean or mode of the population depending upon the 
level of variable measure.  Outliers were identified by inspection of box plots.  Outliers were 
included in analysis using nonparametric tests as these tests are less sensitive to the effects of 
outliers.  Outliers were included in analysis using robust parametric tests that are tolerant of 
violations of normality produced by the effects of outliers.   
Hypothesis Testing 
Univariate analysis was performed to assess the relationship between all demographic 
variables, BMQ, MSSS, and MTSOSD-59R ridit scores and the outcome variable of adherence.  
All independent variables demonstrating a significant relationship to the dependent variable were 
entered into the final logistic regression analysis.   
In addition to the primary research question, ten hypotheses were tested.  Hypothesis 1, 2, 
3, 5, 7, and 9 examined the relationship between one predictor variable and the outcome variable 
of composite adherence group classification.  Given the ordinal level of measure of the 





Hypothesis 4, 6, 8, and 10 explored differences in variable scale scores between composite 
adherence group classifications.  Analysis was performed using independent-samples t test due 
its robust nature in tolerating violations of the assumption of normality.  Independent-samples t 
tests were also used in to assess differences in scores of variable scales between age, gender, and 
time posttransplant groups. 
Spearman Correlation Coefficient 
 Spearman correlation coefficient examines the strength of the relationship between two 
variables.   
H 1:  There will be a significant negative relationship between the predictor variable of  
time posttransplant as measured in years and composite adherence score classification. 
 H 2:  There will be a significant relationship between the predictor variable of age as 
as measured in years and composite adherence classification. 
 H 3:  There will be a significant relationship between medication complexity index scores  
and composite adherence group classifications. 
H 5:  There will be a significant relationship between the predictor variable of health 
beliefs as measured by BMQ Necessity and BMQ Concerns scores and composite adherence 
group classification. 
 H 7:  There will be a significant positive relationship between the predictor variable of 
social support as measured by MSSS subscale and total scale scores and composite adherence 
group classification. 
            H 9:  There will be a significant negative relationship between the predictor variable of 






Independent-Samples t Test  
 Independent-samples t test compares the means of two samples.  While scores should be 
normally distributed, the test is robust and can handle violations of the assumption of normality. 
 H 4:  There will be a significant difference in IST complexity index scores between  
composite adherence group classifications. 
 H 6:  There will be a significant difference in BMQ Necessity subscale, BMQ Concerns  
subscale, and BMQ Necessity / Concerns differential scores between composite adherence group  
classifications. 
 H 8:  There will be a significant difference in MSSS subscale and total scale scores  
between composite adherence group classifications. 
H 10:  There will be a significant difference in MTSOSD-59R total ridit scores between  
composite adherence group classifications. 
 
Logistic Regression 
 Logistic regression seeks to identify which combination of independent variables best 
predicts membership into groups.   
 Primary research question: which of six predictor variables-demographic variables, time 
since transplant, immunosuppressive agents, health beliefs, social support, and symptom 










 Methodological limitations identified in the current study are related to issues with 
design, sampling, measurement, and statistical analysis. 
Design 
 
  Use of a cross sectional, correlational design isolates exploration of the continuum of 
nonadherence to one point in time.  Many researchers in the field hold the belief that  
nonadherence is not an isolated phenomena but rather a dynamic phenomenon that exists on a 
continuum, changing over time, with all patients most likely demonstrating nonadherence 
behavior at any given time.   Within the context of this study, the design limits the assessment of 
nonadherence to one point in time. 
Sampling 
 
 Use of a convenience sampling plan is not without limitations.  Consistent with 
nonprobability methods, there is potential for systematic over or under-representation of 
population elements.   As a result, the sample obtained for this study may not be representative 
of the target population limiting generalizability of findings.  Additional potential for bias exists 
due to the likelihood that adherent participants presenting for annual follow-up are more likely to 









 While a combination of methods was used to measure adherence, each is not without 
limitations.  Self-report measures of adherence run the risk of underreporting nonadherence 
while serum drug assays of drugs with short half-lives provide limited understanding beyond 
recent adherence patterns. A single, isolated serum drug assay was used as the component of 
composite adherence score, rather than assessing variability over several trough blood level 
results.  In addition, clinician collateral reports used in this study were provided by two clinic 
providers, both of whom had limited first-hand knowledge of the patient’s adherence behaviors 
in the year prior to the clinic visit. 
Statistical Analysis 
 
 For the purpose of this study, nonadherence was a dichotomized variable (all or nothing 
phenomena).  While necessary to reduce response bias associated with self-reported measures of 
adherence, dichotomizing the phenomena can result in loss of dimensionality.  Finally, analysis 
of data using logistic regression requires caution when interpreting results as findings do not 
indicate causality but rather demonstrate association and prediction (Polit & Beck, 2008). 
Summary 
 
This research study attempted to examine the impact of six predictor variables-
demographic, time posttransplant, immunosuppressant regimen, health beliefs, social support, 





procedures, a description of study participants, and explanations for the choice of statistical tests 






CHAPTER FOUR:  RESULTS 
 
The purpose of this study was to examine demographic variables, time since transplant, 
immunosuppressive agents, health beliefs, social support, and symptom experience and test their 
relationship to adherence based upon the Health Decision Model (Eraker, Becker, Strecher, & 
Kirscht, 1984).   
The purpose was achieved through the testing of ten hypotheses.  In these hypotheses, 
demographic variables, time since transplant, IST agents, health beliefs, social support, and 
symptom experience were considered independent variables while immunosuppressant 
adherence was considered the dependent variable. 
Data were collected over a fourteen month period.  Combining both participant and 
investigator completed instruments resulted in a total of 91 scale items and 18 demographic 
items.  Data were analyzed using SPSS 19.0 for Windows. 
Description of the Sample 
 Of the 106 individuals approached, a total of 103 (97%) consented to participate. Of 
these, 98 (95%) met final study inclusion criteria and were used in the data analyses.  The sample 
(N = 98) was represented by males (n = 57, 58%) and females (n = 41, 42%) ranging in age from 
25 to 84 years (M = 57.2, SD = 12.75) with 43% (n = 42) of the sample < 55 years of age and 
54.1% (n = 53) of the sample > 55 years of age.  Time posttransplant ranged from 3 years to 14 
years (M=4.9, SD = 1.72) with 67.3% (n =66) of the sample 3-< 5 years posttransplant, and 
32.7% (n = 32) of the sample 6 years or more from transplant.  The typical participant was a 





employed, receiving an annual income ranging between $10,000-$29,999 per year, having some 
college education, and insured by Medicare.   In addition, the typical participant’s IST regimen 
included 2.44 medications and consisted of tacrolimus (Prograf) in combination with either 
mycophenolate sodium (Myfortic) or mycophenolate mofetil (Cellcept) with or without 






Table 2  Demographic Characteristics of the Sample  




    < 55 years of age 





























     Male 








   
Time Posttransplant  
 
Time Posttransplant 
     3-5 years 
     6 years or greater 






























     White 
     African American 
     Asian 
     American Indian / Alaska Native 














   
Ethnicity 
     Not Hispanic or Latino 
     Hispanic or Latino 










   
Marital Status 
    Married / Living Together 
    Single 
    Separated / Divorced 



















Variable n Frequency % Mean  SD Range 
 
Employment Status 
     Not  Currently Employed 
     Full-time (36-40 hours per week) 
     Part-time (< 36 hours per week) 












   
 
Highest Level of Education 
    Some College 
    High School or Equivalent 
    Bachelor’s Degree 
    Vocational / Technical School (2 year) 
    Master’s Degree 

















   
 
Annual Reported Income 
    <$10,000 
    $10,000-$29,999 
    $30,000-$59,999 
    $60,000-$99,999 
















   
 
Primary Insurance 
    Medicare 
    Private Insurance 
    Medicaid 























Variable n Frequency % Mean  SD Range 
 
Immunosuppressant Medication 
    tacrolimus (Prograf)  
    prednisone 
    mycophenolate sodium (Myfortic) 
    mycophenolate mofetil (CellCept) 
    sirolimus (Rapamune) 
    azathioprine (Imuran) 
    lefluonamide (Arava) 





















   
 


























Total Times Per Day Taking Meds 






































Serum Drug Assay 
    tacrolimus (Prograf) 






























Adherence Demographics of Sample 
 A composite adherence score (CAS) (self-report nonadherence, one clinician response of 
“fair” or lower adherence, and non-therapeutic serum drug assay) determined adherence 
classification of study participants.  Of the total sample population (N = 98), 39.8% (n = 39) 
were classified as adherent, with 60.2% (n = 59) identified as nonadherent.  Of the participants 
identified as adherent (n = 39, 39.8%), 59% (n = 23) were males and 41% (n = 16) were females.  
Adherent participants were typically less than 55 years of age (n = 23, 59%) and 5 years or less 
from time of initial transplant (n = 27, 69.2%).  Eighty-three percent (n = 81) of participants 
were adherent to medication taking behaviors while 64.3% (n =63) were adherent to medication 
timing behavior.  Table 3 summarizes adherence demographics of the sample. 
Table 3  Adherence Demographics of Sample 
 
 
Composite Adherence Score 































































Scores on Adherence Measures 
Prior to hypotheses testing, descriptive statistics were obtained to describe and 
summarize data for adherence measures.  Continuous independent variable scores were 
examined for measures of central tendency, outliers, and characteristics of distribution. 
Measures of Central Tendency 
 Measures of central tendency for continuous independent variables were calculated.  
Overall, study participants demonstrated strong beliefs regarding the necessity for taking 
medications.   The mean Necessity Concerns Differential score (m = 2.42) indicated study 
participants rated the beliefs about the necessity for taking medications higher than the concerns 
over taking medicines as further supported by the overall low mean BMQ Concerns subscale 
score.  Of the dimensions of social support, participants perceived greater overall emotional / 
informational social support (m = 33.78).  Participants also experienced a higher degree of 
symptom frequency as compared to symptom distress.  Table 4 summarizes measures of central 


















Age    98    57.17    12.75    25-84 
Time posttransplant 98 4.95 1.72 3-14 
IST Medication Complexity Index 98 24.31 11.56 4-72 
Beliefs About Medicines (BMQ) 
     Necessity subscale 
     Concerns subscale 



















     Tangible (TAN) 
     Positive Social Interaction (POS) 
     Emotional / Informational (EMI) 


















































 Histograms and boxplots were visually inspected to identify outlying cases.  Minimal 
outliers were identified for time posttransplant (2), IST medication complexity index (1), and 
MTSOSD-59R symptom distress total ridit scores (1) with no outliers noted to be severe, 
extending 3 box lengths beyond the plot.  All MSSS scales had identifiable outliers (TAN =6; 
POS =3; EMI =7; AFF =4; MSSS total =7); however, no outliers extended beyond three box 
lengths.  Both BMQ subscales contained minimal outliers (BMQ Necessity =3; BMQ       
Concerns =1) with both including extreme outliers extending beyond 3 box lengths from the plot 
(BMQ Necessity =2; BMQ Concerns =1).   
 All outlying cases were considered to be both minimal in frequency and valid 
components of the sample and were included in the analysis. 
Tests of Normality of Distribution 
 Normality of distribution of all continuous independent variable values / scores (age, time 
posttransplant, IST medication complexity index, BMQ subscales, MSSS subscales, MSSS total 
scale, MTSOSD-59R symptom frequency total ridit, MTSOSD-59R symptom distress total ridit) 
was calculated using measures of skewness, kurtosis, and calculated Kolmogorov-Smirnov (K-S) 
value.  Results showed values for age and scores for the BMQ Concerns, and MTSOSD-59R 
Symptom Frequency total ridit scores were normally distributed within adherence classifications 
as evidenced by both skewness and kurtosis values between -1 and 1 and further supported by 











Skewness Kurtosis Kolmogorov-Smirnov (K-S) p 
Nonadherent Adherent Nonadherent Adherent Nonadherent Adherent Nonadherent Adherent 
Age -.373 -.107 -.423 -.542 .094 .102 .200 .200 





















    Necessity 
    Concerns 
    Necessity  Concerns  


















































    Tangible (TAN) 
    Positive Social  
    Interaction (POS) 
    Emotional /  
    Informational (EMI) 
    Affectionate (AFF) 



































































    Symptom Frequency 







































Estimation of Internal Consistency 
 
Given that the target sample size was achieved, reliability of each of the variable scales 
was estimated by means of Cronbach’s alpha (a).  The BMQ necessity subscale achieved an 
acceptable alpha value greater than .70:  BMQ necessity subscale (n = 98, α =.92).  The BMQ 
concerns subscale (n = 98, α = .68) fell just short of an acceptable estimate.  These alphas 
compared favorably to those reported by earlier researchers:  BMQ necessity subscale (α = .55) 
and BMQ concerns subscale (α = .73) (Horne et al., 1999).   
All subscales of the MSSS social support scale  as well as the total MSSS scale score 
achieved equally acceptable alpha values:  four item TAN (n = 98, α = .93), eight item EMI (n = 
98, α = .95), three item AFF (n = 98, α = .88), three item POS (n = 98, α = .93), and eighteen 
item MSSS total score (n = 98, α = .96).  Values compared favorably to previously published 
values:  TAN (n = 98, α = .84), EMI (n = 98, α = .80), AFF (n = 98, α = .86), POS (n = 98, α = 
.87), and MSSS total score (n = 98, α = .88) (National Multiple Sclerosis Society, 1997).  Table 6 
summarizes internal consistency estimation values. 
Consistent with previous research reporting psychometric properties of the MTSOSD-
59R scale, internal consistency was not appropriate or permitted and thus not estimated for the 










Table 6  Estimation of Internal Consistency as Reliability 
Instrument N  of items Chronbach’s alpha 
Beliefs About Medicines (BMQ) 
     Necessity 








Modified Social Support Scale (MSSS) 
     Tangible (TAN) 
     Emotional / Informational (EMI) 
     Affectionate (AFF) 
     Positive Social Interaction (POS) 
















 Ten hypotheses were posed based on the Health Decision Model as adapted for use in 
this study (see Figure 1).  Due to the dichotomous nature of the dependent variable, the 
relationship between independent variables and composite adherence group classifications 
(hypotheses 1, 3, 5, 7, and 9) were tested using Spearman’s correlation coefficient. The robust 
independent samples t tests was used to test for differences in mean independent variable scores 
among adherence classification groups and specified demographic groups (age, gender, time 
posttransplant).  Independent variables that demonstrated a significant relationship to adherence 
group classification were entered into the final regression analysis. 
Categorical Demographic Variables 
 A two-tailed Spearman’s rho correlation coefficient was calculated for the relationship 
between the categorical demographic variables of age groups, gender, race, ethnicity, marital 





A low, negative correlation that was significant (r = -.213, p=.035) was found between age as 
grouped into younger (< 54 yrs) and older (> 55 yrs) participants.  Older (> 55 yrs) transplant 
recipients were less adherent than younger (< 54 yrs) recipients.  Table 7 summarizes correlation 
statistics for all categorical demographic variables. 
Table 7  Correlations Between Demographic Characteristics and Composite Adherence Groups 
Demographic Variable n r p (two-tailed) 
Age  group (<54yrs; > 55yrs) 98 -.213 .035 
Gender 98 -.013 .896 
Race 98 -.111 .275 
Ethnicity 98 .063 .540 
Marital status 98 -.129 .207 
Education 98 -.048 .638 
Insurance 98 -.050 .628 
Income 98 -.053 .605 
Time posttransplant groups (< 5 yrs; > 6 yrs)  98 -.033 .750 
* p <.05 
Hypothesis 1 
 Hypothesis 1:  There will be a significant negative relationship between the predictor 
variable of time posttransplant as measured in years and composite adherence group 
classification.   
 A one –tailed Spearman’s rho  correlation coefficient was calculated for the relationship 
between the predictor variable of time posttransplant as measured in years and composite 
adherence group classification.  A weak, negative correlation was found (r = -.053, p=.303).  The 
research hypothesis was rejected.  Time posttransplant was not related to composite adherence 








 Hypothesis 2:  There will be a significant relationship between the predictor variable of 
age as measured in years and composite adherence group classification. 
 A two-tailed Spearman’s rho correlation coefficient was calculated for the relationship 
between the predictor variable of age as measured in years and composite adherence group 
classification.  A weak, negative correlation that was found (r = -.159, p = .118).  The hypothesis 
was rejected.  There was no significant relationship between the predictor variable of age as 
measured in years and composite adherence group classification. 
Hypothesis 3 
 Hypothesis 3:  There will be a significant relationship between medication complexity 
index scores and composite adherence group classification. 
 A two-tailed Spearman’s rho correlation coefficient was calculated for the relationship 
between the predictor variable of medication complexity index scores and composite adherence 
group classification.  A weak, negative correlation that was found (r = -.038, p = .711).  The 
hypothesis was rejected.  There was no significant relationship between medication IST 
complexity index scores and composite adherence group classification. 
Hypothesis 4 
 Hypothesis 4:  There will be a significant difference in IST medication complexity scores 
between composite adherence group classifications. 
 IST medication complexity index scores of nonadherent and adherent adult renal 
transplant recipients were compared using an independent –samples t test.  Levene’s test for 





distributed.  No significant difference was found (t (96) = .283, p=.778).  Hypothesis 4 was 
rejected.  Nonadherent and adherent participants had similar IST complexity scores.  Table 8 
summarizes results. 
Table 8  Group Differences for IST Medication Complexity Scores-Adherent / Nonadherent 
Variable / Group Minimum Maximum M SD t (df) P* 
 





























*p < .05 
 Additional t-test analysis was conducted comparing the mean IST complexity index 
scores between males and females, younger (< 54 yrs) and older (> 55 years) participants, and 
time posttransplant groups as grouped around the mean (< 5 yrs posttransplant and 6 yrs or more 
posttransplant).  While no significant differences in complexity scores were found between 
gender and age groups, the mean IST complexity score of participants 5 years or less 
posttransplant was significantly lower (m = 22.24, sd = 12.095) than the means scores of 
participants 6 or more years from transplant (m = 28.56, sd = 9.147).  Table 9 summarizes group 









Table 9  Group Differences for IST Medication Complexity Scores-Gender, Age Groups, Time 
Posttransplant Groups 
Variable / Group Minimum Maximum M SD t (df) P* 
Gender (N=98) 
     Male (n=57) 



















Age (N =98) 
    < 54 yrs (n=45) 


















Time posttransplant (n = 98) 
    < 5 yrs (n = 66) 

















*p < .05 
Hypothesis 5 
 Hypothesis 5:  There will be a significant relationship between the predictor variable of 
health beliefs as measured by the BMQ Necessity and BMQ Concerns subscale score and 
composite adherence group classification. 
 A Spearman’s rho correlation coefficient was calculated for the relationship between 
BMQ Necessity and BMQ Concerns subscales of the Beliefs About Medicines Questionnaire 
and composite adherence group classification.  A low, positive correlation that was not 
significant was found between the BMQ necessity subscale (r = .160, p = .116) and composite 
adherence group classification.  A low, negative correlation that was not significant was found 
between the BMQ concerns subscale (r = -.124, p = .223) and composite adherence group 
classification.  Hypothesis 5 was rejected.  Scores on both the BMQ Necessity and BMQ 







 Hypothesis 6:  There will be a significant difference in BMQ Necessity subscale scores, 
BMQ Concern subscale scores, and BMQ Necessity/Concerns Differential scores between 
composite adherence group classifications. 
 Independent-samples t tests were calculated comparing the mean BMQ Necessity, BMQ 
Concerns, and BMQ Necessity/Concerns Differential scores between adherent and nonadherent 
participants.  Table 10 summarizes results with the reported p values reflective of the Levene’s 
statistic.  Hypothesis 6 was rejected as no significant differences were found in scores between 
groups.  The mean scores of nonadherent participants were not significantly different from the 
mean scores of adherent participants across all BMQ scores.   
Table 10  Group Differences for Nonadherent / Adherent Groups-Beliefs About Medicines 
Variable / Group  Minimum Maximum M SD t (df) P* 
BMQ Necessity (N = 98) 
    Nonadherent (n = 59) 


















BMQ Concern (N =98) 
    Nonadherent (n = 59) 


















Necessity / Concerns Differential 
(N =98) 
    Nonadherent (n = 59) 























*p < .05 
Additional analyses were conducted comparing the mean BMQ scale scores between 
males and females, younger (< 54 yrs) and older (> 55 years) participants, and time 
posttransplant groups (< 5 yrs posttransplant and 6 yrs or more posttransplant).  Reported p 






























     Male (n=57) 




















Age (N =98) 
    < 54 yrs (n=45) 


















Time posttransplant (n = 98) 
    < 5 yrs (n = 66) 




































     Male (n=57) 



















Age (N =98) 
    < 54 yrs (n=45) 


















Time posttransplant (n = 98) 
    < 5 yrs (n = 66) 









































     Male (n=57) 



















Age (N =98) 
    < 54 yrs (n=45) 


















Time posttransplant (n = 98) 
    < 5 yrs (n = 66) 






























 Hypothesis 7:  There will be a significant positive relationship between the predictor 
variable of social support as measured by MSSS total and subscale (TAN, POS, EMI, AFF) 
scores and composite adherence group classification. 
 A one-tailed Spearman’s rho correlation coefficient was calculated for the relationship 
between all MSSS subscale scores and total scale scores and composite adherence group 
classification.  Low, positive correlations that were significant were found between the Tangible 
Support (TAN) subscale (r = .215, p =.017), Emotional Informational Support (EMI) subscale   
(r = .274, p = .003), Positive Social Interaction (POS) subscale (r = .199, p = .025), MSSS total 
scale scores (r = .274, p =.003) and composite adherence group classification.  A low, positive 
correlation that was not significant was found between the Affectionate Support (AFF) subscale 
(r = .054, p = .297) and composite adherence group classification.  The hypothesis was partially 
accepted.  Participants that were adherent perceived significantly greater tangible, 
emotional/informational, positive social interaction, and overall social support than 
nonadherent participants.   
Hypothesis 8 
Hypothesis 8:  There will be a significant difference in MSSS subscale and total scale 
scores between composite adherence group classifications. 
 Independent-samples t tests were calculated comparing all mean MSSS subscale (TAN, 
POS, EMI, AFF) scores and total MSSS scale scores between adherent and nonadherent 
participants.  Reported p values reflect the Levene’s test for equality of variances.  A significant 





POS subscale (t (95) = -2.1.06, p =.038), and MSSS total scale scores (t (96) = -2.261, p =.026) 
and composite adherence group classification.  The mean scores of the nonadherent group for 
emotional, positive social interaction, and total overall social support were significantly lower 
than the mean scores of adherent participants.  Hypothesis 8 was partially accepted.  There was a 
significant different between the mean scores of the EMI, POS, and MSSS total scale scores for 
nonadherent and adherent participants.  Table 12 summarizes results. 
Table 12 Group Differences for Nonadherent / Adherent Groups-Modified Social Support  
Scales 
Variable / Group  Minimum Maximum M SD t (df) P* 
TAN (N = 98) 
    Nonadherent (n = 59) 


















EMI (N =98) 
    Nonadherent (n = 59) 



















AFF (N = 98) 
    Nonadherent (n = 59) 


















POS (N = 98) 
    Nonadherent (n = 59) 


















MSSS total score (N = 98) 
    Nonadherent (n = 59) 

















*p < .05 
Additional analyses were conducted comparing the mean MSSS subscale scores (TAN, 
POS, EMI, AFF) and  MSSS total scale scores between males and females, younger (< 54 yrs) 





yrs or more posttransplant).  Reported p values were based on Levene’s test for equality of 
variances. 
While no significant differences were found between the mean scores of age groups and 
time posttransplant groups, a significant difference between the mean scores of men and women 
on the TAN subscale (t (64) = 2.842, p = .006), AFF subscale (t (96) = 2.081, p = .040), and 
MSSS total scale score (t (96) = 2.263, p = .026).  The mean TAN, AFF, and MSSS total scale 
scores for men were significantly higher than women.  Table 13 summarizes test results. 
 





Table 13  Group Differences for Gender, Age Groups, Timeposttransplant Groups-Modified Social Support Scales 
 
Group  














     Male (n=57) 


















Age (N =98) 
    < 54 yrs (n=45) 


















Time posttransplant (n = 98) 
    < 5 yrs (n = 66) 



































     Male (n=57) 


















Age (N =98) 
    < 54 yrs (n=45) 



















Time posttransplant (n = 98) 
    < 5 yrs (n = 66) 







































     Male (n=57) 


















Age (N =98) 
    < 54 yrs (n=45) 


















Time posttransplant (n = 98) 
    < 5 yrs (n = 66) 



































     Male (n=57) 


















Age (N =98) 
    < 54 yrs (n=45) 


















Time posttransplant (n = 98) 
    < 5 yrs (n = 66) 








































     Male (n=57) 



















Age (N =98) 
    < 54 yrs (n=45) 



















Time posttransplant (n = 98) 
    < 5 yrs (n = 66) 
























 Hypothesis 9:  There will be a significant negative relationship between the predictor 
variable of symptom experience as measured by MTSOSD-59R total ridit scores and composite 
adherence group classification. 
 A one-tailed Spearman’s rho correlation coefficient was calculated for the relationship 
between total ridit scores for MTSOSD-59R Symptom Occurrence and Symptom Distress scales  
and composite adherence group classification.  A low negative correlation that was not 
significant was found (r = -.162, p = .055) for the relationship between Symptom Frequency 
total ridit scores and composite adherence group classification. A low, negative correlation that 
was also not significant was found (r = -.143, p =.081) between Symptom Distress total ridit 
scores and composite adherence group classification.  Hypothesis 9 was rejected.  There was no 
significant relationship between symptom experience and composite adherence group 
classification.  Table 14 identifies by rank order, the most prominent symptoms and associated 
distress experienced by gender, age, time posttransplant, and adherence groups.   
 Additional analyses were conducted to determine the relationship between individual 
symptoms and composite adherence group classification.  Three symptoms demonstrated a 
significant relationship with composite adherence group classification.  Dizziness (r = .288, p 
=.037), difficulty concentrating and / or memory problems (r = -.327, p =.016), and chest pain   
(r = -.471, p =.036) demonstrated significant relationships with adherence group classification. 
Adherent participants experienced significantly less chest pain, dizziness, and difficulty 






Table 14 Symptom Distress-Gender, Age, Time Posttransplant, Adherence  
 














Males Females Males Females 
n % n % n % n % 
Tiredness 65 (66.3) 13 41.9 12 35.3 18 58.1 22 64.7 
Wind 61 (62.2) 17 51.5 9 32.1 16 48.5 19 67.9 
Lack of Energy 59 (60.2) 11 32.4 5 20 23 67.6 20 80 
Bruise Easy 57 (58.2) 9 33.3 5 16.7 18 66.7 25 83.3 
Joint Pain 56 (57.1) 11 34.4 9 37.5 21 65.6 15 62.5 
Restlessness / Nervousness 56 (57.1) 3 9.7 4 16.0 28 90.3 21 84 
Concentration / Memory Problems 54 (55.1) 13 40.6 9 40.9 19 59.4 13 59.1 
Dizziness 53 (54.1) 3 10.7 3 12 25 89.3 22 88 
Sleep Difficulties 52 (53.1) 5 16.7 10 45.5 25 83.3 12 54.5 
Muscle Weakness 47 (48.0) 4 16.0 5 22.7 21 84 17 77.3 





















< 54 yrs > 55 yrs < 54 yrs > 55 yrs 
n % n % n % n % 
Tiredness 65 (66.3) 12 42.9 13 35.1 16 57.1 24 64.9 
Wind 61 (62.2) 10 40 16 44.4 15 60 20 55.6 
Lack of Energy 59 (60.2) 5 19.2 11 33.3 21 80.8 22 66.7 
Bruise Easy 57 (58.2) 7 5.6 7 8.4 16 69.6 27 47.4 
Joint Pain 56 (57.1) 9 39.1 11 33.3 14 60.9 22 66.7 
Restlessness / Nervousness 56 (57.1) 1 4.3 6 18.2 22 95.7 27 81.8 
Concentration / Memory Problems 54 (55.1) 12 60 10 29.4 8 40 24 70.6 
Dizziness 53 (54.1) 2 9.5 4 12.5 19 90.5 28 87.5 
Sleep Difficulties 52 (53.1) 5 21.7 10 34.5 18 78.3 19 65.5 
Muscle Weakness 47 (48.0) 6 28.6 3 11.5 15 71.4 23 88.5 






















< 5 yrs 
posttransplant 
> 6 yrs 
posttransplant 
< 5 yrs 
posttransplant 
> 6 yrs 
posttransplant 
n % n % n % n % 
Tiredness 65 (66.3) 16 38.1 9 39.1 26 61.9 14 60.9 
Wind 61 (62.2) 17 45.9 9 37.5 20 54.1 15 62.5 
Lack of Energy 59 (60.2) 12 28.6 4 23.5 30 71.4 13 76.5 
Bruise Easy 57 (58.2) 8 22.2 6 28.6 28 77.8 15 71.4 
Joint Pain 56 (57.1) 16 42.1 4 22.2 22 57.9 14 77.8 
Restlessness / Nervousness 56 (57.1) 3 8.1 4 21.1 34 91.9 15 78.9 
Concentration / Memory Problems 54 (55.1) 13 38.2 9 45 21 61.8 11 55 
Dizziness 53 (54.1) 5 14.3 1 5.6 30 85.7 17 94.4 
Sleep Difficulties 52 (53.1) 11 32.4 4 22.2 23 67.6 14 77.8 
Muscle Weakness 47 (48.0) 9 29 0 0 22 71 16 100 





















Nonadherent Adherent Nonadherent Adherent 
n % n % n % n % 
Tiredness 65 (66.3) 14 32.6 11 50 29 67.4 11 50 
Wind 61 (62.2) 16 42.1 10 43.5 22 57.9 13 56.5 
Lack of Energy 59 (60.2) 10 27.8 6 26.1 26 72.2 17 73.9 
Bruise Easy 57 (58.2) 11 28.2 3 16.7 28 71.8 15 83.3 
Joint Pain 56 (57.1) 16 40 4 25 24 60 12 75 
Restlessness / Nervousness 56 (57.1) 4 10.8 3 15.8 33 89.2 16 84.2 
Concentration / Memory Problems 54 (55.1) 12 30.8 10 66.7 27 69.2 5 33.3 
Dizziness 53 (54.1) 1 3.3 5 21.7 29 96.7 18 78.3 
Sleep Difficulties 52 (53.1) 10 27 5 33.3 27 73 10 66.7 
Muscle Weakness 47 (48.0) 7 21.9 2 13.3 25 78.1 13 86.7 







 Hypothesis 10:  There will be a significant difference in MTSOSD-59R total ridit scores 
between composite adherence group classifications. 
 An independent-samples t test was calculated comparing the mean MTSOSD-59R 
Symptom Frequency and Symptom Distress total ridit scores of nonadherent and adherent long-
term adult renal transplant recipients.  No significant difference was found between groups for 
both Symptom Frequency total ridit scores (t (96) = 1.704, p = .092) and Symptom Distress total 
ridit scores (t (96) = 1.232, p = .221).  The mean scores of adherent participants were not 
significantly different from nonadherent participants for both the MTSOSD-59 R Symptom 
Frequency and Symptom Distress total ridit scores.  Table 15 summarizes group scores. 
Table 15 Group Differences Nonadherent / Adherent-MTSOSD-59R Symptom Occurrence and  
Symptom Distress Total Ridit Scores 
 Variable / Group  Minimum Maximum M SD t (df) P* 
MTSOSD-59R Symptom Frequency 
    Nonadherent (n = 59) 



















MTSOSD-59R Symptom Distress 
    Nonadherent (n = 59) 


















*p < .05 
Additional analyses were conducted comparing the means of Symptom Frequency and 
Symptom Distress total ridit scores between males and females, younger (< 54 yrs) and older (> 
55 years) participants, and time posttransplant groups (< 5 yrs posttransplant and 6 yrs or more 
posttransplant).  The reported p value reflected the Levene’s statistic.  No significant difference 





 Table 16 Group Differences Gender, Age Groups, Time Posttransplant Groups-MTSOSD- 
59R Symptom Occurrence and Symptom Distress Total Ridit Scores 
 
Group  














     Male (n=57) 


















Age (N =98) 
    < 54 yrs (n=45) 



















Time posttransplant (n = 98) 
    < 5 yrs (n = 66) 



































     Male (n=57) 


















Age (N =98) 
    < 54 yrs (n=45) 



















Time posttransplant (n = 98) 
    < 5 yrs (n = 66) 


























Logistic Regression Analysis 
 To answer the primary research question of which of six predictor variables  
demographic variables, time since transplant, immunosuppressive agents, health beliefs, social 
support, and symptom experience are most influential in predicting IST adherence in long-term 
adult  renal transplant recipients, a forward logistic regression was conducted.  Predictor 
variables demonstrating a significant relationship to adherence (age groups, TAN subscale, POS 
subscale, EMI subscale, and MSSS total scale scores) were entered into the final logistic 
regression analysis.  
Prior to analysis, data were explored for missing values and outliers.  Preliminary 
multiple linear regression analysis was conducted to calculate Mahalanobis distance and to 
evaluate multicollinearity.  Initial results indicated multicollinearlity was violated as tolerance 
statistics were less than .1 for all social support scales.  To address this problem, the independent 
variable of MSSS total scale score was removed.  The resultant table of regression coefficients 
(see Table 18) indicated multicollinearity was not violated since tolerance statistics for all three 
independent variables were greater than 0.1.  Data were explored to determine which cases 
exceeded the Mahalanobis distance critical value of x2 (3) = 16.266 at p = .001.  One subject 












(TAN)Tangible Support Subscale  .587 1.705 
(EMI) Emotional Informational Support Subscale .297 3.366 
(POS) Positive Social Interaction Subscale  .366 2.732 
 
Binary logistic regression using the Forward:  LR method was then conducted to 
determine which independent variables (age [< 54 yrs, > 55 yrs], TAN subscale, EMI subscale, 
POS subscale) were predictors of adherence group classification (adherent/nonadherent).    
Regression results indicated the overall model of two predictors (age [< 54 yrs, > 55 yrs] and 
EMI subscale) was statistically reliable in distinguishing between adherent and nonadherent 
participants (-2 Log Likelihood 116.244; Goodness-of-Fit x2 (2) = 13.664, p = .001).  The model 
correctly classified  69.1% of the cases.  Regression coefficients are presented in Table 18.  Wald 
statistics indicated that age (< 54 yrs, > 55 yrs) and EMI subscale significantly predicted 
adherence group classification.  Odds ratios for the EMI (eB = 1.105) variable indicated that as 
the variable EMI increases by 1, participants were 1.105 times more likely to be classified as 
adherent.  Odds ratio for the variable age grouped (eB = 3.320) indicated that as age grouped 










Table 18 Regression Coefficients 
 B Wald df p Odds Ratio 95% Confidence 
Interval 
Lower Upper 
EMI (Emotional  / Informational ) 
subscale 
.100 7.028 1 .008 1.105 1.026 1.189 
Age group (< 54 yrs; > 55 years) 1.200 6.871 1 .009 3.320 1.354 8.144 
Constant -4.435 10.142 1 .001    
 
Summary 
 The results of this study demonstrated weak, but significant relationships between age 
group, TAN subscale, POS subscale, EMI subscale, and MSSS total scale scores and adherence 
group classification.  While perceived emotional and information social support and being older 
significantly predicted adherence, odds ratios demonstrated moderate change in the likelihood of 
adherence on the basis of a one unit change in age or perceived emotional/informational support.  
Thus, age and perceived emotional/informational support distinguished moderately between 






CHAPTER FIVE:  DISCUSSION 
 
During the past ten years, many studies have explored predictors of immunosuppressant 
(IST) medication adherence in adult renal transplant recipients.  To date, this is the first study to 
examine predictors of IST medication adherence in a population of long-term renal transplant 
recipients.  The purpose of this study was to examine demographics, time posttransplant, 
immunosuppressive agents, health beliefs, social support, and symptom experience and test their 
relationship to IST adherence based upon the Health Decision Model as adapted by the principal 
investigator for use in this study.  This chapter compares and contrasts study findings with results 
reported in previous research.  Implications for nursing practice as well as recommendations for 
future research are discussed. 
Sample 
 
 While the sample in this study was similar to the U.S. renal transplant population as 
reported by the Organ Procurement Transplant Network (2009), study findings should not be 
generalized to the entire population.  This study sample was similar to the U.S. renal transplant 
population in terms of gender (58.2% men versus 60.4% nationally).  Age group distributions 
indicated a slightly older population in this study (see Table 19).  Finally, while African 
Americans were appropriately represented (27.6% versus 25.7% nationally), Asian and “other” 









Table 19  Comparison of Study Participants and U.S. Transplant Population 
Characteristic Study (%) U.S. Transplant Population (%) 
Age 
  18-34 
  35-49 
  50-64 












  Male 








  White 
  Black 
  Asian 




















 Though healthcare providers in this study setting considered long-term recipients 
generally adherent, 60.2% of this study’s participants were nonadherent to their 
immunosuppressant medications when defined as older (> 55 yrs) in this study.  Variations in 
methods of measuring IST adherence have contributed to the wide range of previously reported 
adherence rates.  When measured by self-report methods, IST adherence is often overestimated 
(Osterberg & Blaschke, 2005).  In contrast, a study by Russell et al. (2010) noted that use of a 
self-report measure of adherence that captures timing adherence behaviors may contribute to an 
overall low percentage of adherent participants in a sample where 86% of older renal transplant 





One study to date has used a composite score of adherence, similar to the one used for 
this study.  The composite score, used by Schmidt-Mohler et al. was composed of clinician 
collateral reports and the same self-report measure used in this study (BAASIS) which captures 
timing adherence (Schmid-Mohler, Thut, Wüthrich, Denhaerynck, & De Geest, 2010).  Authors 
of this study categorized participants as adherent, partially adherent, or nonadherent.  However, 
if findings were dichotomized, 76% of the sample would have been classified as nonadherent 




 The majority of studies have reported younger age as being associated with nonadherence 
(Chisholm-Burns, Kwong, Mulloy, & Spivey, 2008; M. A. Chisholm, Lance, & Mulloy, 2005; 
Denhaerynck et al., 2007; Frazier, Davis-Ali, & Dahl, 1994; Ghods, Nasrollahzadeh, & Argani, 
2003; Greenstein & Siegal, 1998; Gremigni et al., 2007).  Of these studies, few have clearly 
defined younger and older age categories.  In this study, age was assessed both as a continuous 
variable and older/younger categorical variable.  While findings from this study failed to 
correlate age (continuous variable) with adherence, a significant, low negative correlation was 
found when grouping participants into older and younger age groups.  Older transplant recipients 
(> 55 yrs) were identified as being less adherent than younger participants (< 54 yrs).  Recent 
studies defining “older” age groups yielded similar results with Chisholm-Burns et al. (2008) 
reporting adherence as being lower among recipients 60 or more years of age and Russell et al. 







 The mean time posttransplant for participants in this study was 4.95 yrs.  Analysis failed 
to support a significant relationship between time posttransplant and adherence.  Findings from 
this study contrast with the majority of studies that reported increased time from transplant as 
being significantly associated with nonadherence (Chisholm-Burns, et al., 2008; Chisholm, et al., 
2005; Chisholm, Mulloy, & DiPiro, 2005; Greenstein & Siegal, 1998; Ichimaru et al., 2008).  
While earlier research findings support an inverse relationship between time posttransplant and 
adherence to IST medications, one study to date has defined time posttransplant quartiles in an 
effort to isolate the most useful time posttransplant to reinforce adherence.  Chisholm-Burns et 
al. (2008) concluded that recipients who were 4 years or less from transplant had higher overall 
adherence to immunosuppressive medications than those 5 or more years from transplant 
identifying a useful point for targeted interventions by healthcare providers.  Both the frequency 
of medication adjustments and follow-up appointments that occur during the first two years 
following transplant could explain these findings.  Given the lack of association between time 
posttransplant (m=4.95 yrs) and adherence in this study, the quality of long-term primary care 
provided by both the local primary care providers and the transplant clinic could be a possible 
factor influencing long-adherence.  Additionally, limited research has explored the effect of 
comorbidities and their associated treatments (e.g. more medications) on IST adherence.  The 









 A calculated medication complexity index score (number of medications x number of IST 
pills taken per day x number of times per day taking IST medications) was used to determine the 
relationship between IST medications and adherence.  Although no study to date conducted 
within the adult renal transplant population has used this method of measure, all components of 
the measure have been used either alone or in combination in many previous studies.  Using this 
method of measure, nonadherent participants were found to have a higher mean IST complexity 
index score (m=24.58) than adherent participants (m=23.90), but the difference was not 
statistically significant.  In addition, study findings failed to find a significant relationship with 
adherence.  Results from previous studies are mixed (Goldfarb-Rumyantzev et al., 2011; 
Schmid-Mohler, et al., 2010; Sketris et al., Vasquez, Tanzi, Benedetti, & Pollak, 2003; Weng et 
al., 2005) with several factors providing possible explanations.  While this study included only 
IST medications in the analysis, other studies included either all prescribed medications or did 
not clearly indicate which medications were used in the final analysis.  In addition, the types of 
medications, dosing frequencies, and medication regimens (combination or triple therapy) used 
in previously reported studies reflected those represented in this study.  However, the method or 
combination of methods used to measure the dependent variable of adherence varied across all 
studies.  Finally, included in many study samples were participants in the immediate 
posttransplant period (first 6 months) up to as few as 1-2 years posttransplant; the times during 
which doses are frequently adjusted and/or medications weaned off and discontinued 





Beliefs About Medicines 
 
 Findings from this study failed to support a significant relationship between beliefs about 
medicines and adherence.  These results are in contrast to those reported by Butler et al. (2004) 
who concluded a lower belief in the need for medications was associated with nonadherence.  
While results from this study indicated  nonadherent participants has lower beliefs in the need for 
medicines as reported by the mean Necessity scale score (m= 22.58 nonadherent versus m=23.67 
adherent), the results failed to achieve statistical significance.  One possible explanation for this 
failure was the presence of a nonnormal distribution as influenced by Necessity scale score 
outliers. 
 Additional study findings not achieving statistical significance in this study, may be of 
clinical significance to healthcare providers.  As compared to younger (< 54 yrs) participants, 
older participants (> 55 yrs) had lower beliefs in the need for medicines and greater concerns 
over the consequences of taking medicines.  In addition, females demonstrated lower beliefs in 
the need for medicines yet greater concern over the consequences of taking medicines.  While 
concerns over the consequences of taking medicines were virtually the same in both time 
posttransplant groups (< 5 yrs, > 6 yrs), participants six or more years from transplant reported 
lower beliefs in the need for medicines, which ultimately could influence adherence.   
Social Support 
 
 Limited studies have explored social support within the context of IST adherence in the 
adult renal transplant population.  Of those that have, results have been mixed.  Using the Social 





for, respected, and involved with family and friends, Russell et al. (2010) reported no significant 
relationship between social support and IST adherence in a population of older (> 55 years) 
recipients.   
Using the shorter 5 item version of the Modified Social Support Scale (MSSS), 
Chisholm-Burns et al. (2010) reported a significant relationship between social support and IST 
adherence with affectionate support and an instrumental support item (help with household 
functions) as being associated with total adherence summary scores.  Of note in the Chisholm-
Burns et al. (2010) study was the reported mean age (m =48.9) of the sample. 
 Findings reported in this study, using the 18 item MSSS scale, mirrored findings reported 
by Chisholm-Burns et. al. (2010) noting a significant relationship between social support and 
increased adherence.  However, contrary to findings reported by Chisholm-Burns et. al. (2010), 
results from this study did not support a significant relationship between affectionate support 
subscale items and adherence.  One possible explanation for this finding could be the higher 
overall percent of participants in this study that reported being married or living together (70.4%) 
versus the lower percent of married participants in the Chisholm-Burns et. al. (2010) study 
(28.7%).   
Symptom Experience 
 
 Results obtained in this study failed to demonstrate a significant relationship between 
symptom experience and adherence as measured by total overall symptom frequency and 
symptom distress total ridit scores.  In addition, results comparing differences in age, gender, 





normal distribution of both symptom frequency and symptom distress total ridit scores.  While 
reported findings were not statistically significant, results comparing differences in groups may 
be of clinical significance to healthcare providers. 
 It is important to note that no study to date has explored the relationship between 
symptom experience and adherence using the updated MTSOSD-59R instrument reflective of 
current IST regimens.  In addition, of the studies exploring the effect of symptom experience on 
adherence, all have been conducted within European or Canadian populations (Butler et al., 
2004; Denhaerynck et al., 2007; Sketris et al., 1994; Teixeira De Barros & Cabrita, 1999).  This 
study is the first to obtain data from a U.S. sample. 
 Findings reported in this study noted higher mean overall symptom frequency 
[nonadherent (m = 30.64), adherent (m = 28.54)] and symptom distress ridit scores [ nonadherent 
(m =10.42), adherent (m = 8.88)] in nonadherent participants, though results were not significant.  
A study conducted by Teixeira De Barros and Cabrita (1999) in a population of Portuguese renal 
transplant recipients using the MTSOSD 45 item scale reported similar results with significantly  
higher overall symptom frequency and symptom distress ridit scores in nonadherent participants.  
Perhaps the failure to achieve statistical significance in this study is due to possible cultural 
variations in the measured level of symptom experience.   
 Age related findings reported in this study were in contrast to those reported by Teixeira 
De Barros et al. (1999) who identified significantly higher mean symptom frequency scores in 
older participants (> 40 yrs).  Findings reported in this study noted younger participants (< 54 
yrs) as having higher, though nonsignificant, overall mean symptom frequency scores.  Mean 





similar findings in the study by Teixeira De Barros et al. (1999).  Cultural variations, variations 
in IST regimens, instruments versions used to measure symptom experience, and variations in 
defined age groups are all factors possibly influencing conflicting results. 
 Finally, no study to date has explored differences in symptom experience between groups 
based on time posttransplant.  Results in this study noted participants who were six or more years 
from transplant had lower, though nonsignificant, mean symptom distress scores and higher 
mean symptom frequency scores than participants who were 5 years or less from transplant.  
Perhaps the higher mean symptom frequency scores found in those participants 6 or more years 
from transplant is due to the development of symptoms similar to those associated with IST 
therapy but also associated with comorbid conditions that can develop as a result of long-term 
IST therapy (diabetes, hypertension).  Conversely, perhaps the lower mean symptom distress 
scores found in the same time posttransplant group (> 6 yrs time posttransplant) can be attributed 
to tolerance or lessening of the intensity of symptom distress over time.  Research in this area is  




Findings reported in this study add to the body of knowledge concerning IST adherence  
in adult renal transplant recipients by focusing on a population defined as long-term.  While 
results from this study have implications for nursing education, practice, and policy, the greatest 








Of the 96,918 patients currently awaiting renal transplantation in the United States, 
41,678 (43%) of those awaiting transplant are between 50 and 64 years of age (OPTN, 2012).  
Results of this study demonstrate a negative correlation between age groups and adherence with 
older (> 55 yrs) participants being less adherent than younger participants.  Given the higher 
percentage of nonadherent participants in this study (60%) and the mean age of participants in 
this study (57.19 yrs), multidisciplinary teams providing care for long-term transplant recipients 
may want to consider the findings in this study and implement both adherence screening 
measures as well as  interventions directed at modifiable variables associated with adherence in 
this age group.  
Nurses and advanced nurse practitioners working in outpatient clinic settings, may 
consider screening patients in this age group annually for nonadherence by using a feasible 
measure of self-report such as the BAASIS.  Nurses could educate patients screened as 
nonadherent about the use of reminder methods to enhance adherence (e.g. pillboxes, storing 
medications with other items associated with daily rituals, keeping medications in the same 
location).  In addition, if medication complexity involving IST medications as well as 
medications for other comorbid conditions is high, nurse practitioners collaborating with  
nephrologists could review regimens in an effort to simplify medication dosing regimens to 
promote better adherence. 
Emotional/information social support, consisting of physical comforting, listening, and 
empathizing along with the giving of advice and sharing information, was statistically reliable in 





support networks over the lifespan, licensed social workers as members of a multidisciplinary 
team could be involved in both screening for changes in social networks in this age group as well 
as integral in facilitating appropriate interventions. 
For nonadherent patients demonstrating a lack of perceived emotional/informational 
social support systems, a few interventions may be considered.  The use of support groups is 
common during the pretransplant phase of care to aid patients in determining if transplantation as 
a therapy is an appropriate choice.  Continuing these same support group sessions during the 
posttransplant phase of care may provide recipients who are experiencing changes in social 
support networks with a group of individuals able to provide relevant advice and information 
during times of need.   
Policy 
 
 The major focus of public policy addressing IST medication adherence in adult renal 
transplant recipients is on extending lifetime Medicare coverage for costs related to IST therapy 
to those patients receiving Medicare benefits for reasons other than disability.  The results of this 
study do not contribute to those policy initiatives. 
 While not public policy, findings from this study could be used to influence national  
standards of care for kidney transplant recipients.  Current Kidney Disease:  Improving Global 
Outcomes (KDIGO) practice guidelines for the care of kidney transplant recipients calls for 
preventing, detecting, and treating nonadherence (Kasiske, Zeier, Chapman, Craig, Ekberg et al., 
2009).  Given the relationship between social support and adherence, providing a measure for 





nonadherence may be of value in primary care settings.  Findings also support the need for more 
research funds to support the study of adherence in recipients in the United States. 
Nursing Education 
 
 Results reported in this study may encourage both entry level and advanced practice 
nursing education programs to incorporate content addressing the impact social support has on 
adherence in long-term renal transplant recipients.  More importantly, as part of ongoing support 
and care provided over the lifespan of the transplant recipient, both the patient and family should 
be periodically assessed for changes in social support structure as well as educated on the 
importance of sustained social support and its relationship to adherence.  Nurses also need 
information on IST medications to better assist in patient teaching and follow-up care.  
Necessary IST medication information such as drug-to-drug interactions, food-drug interactions, 
side-effects, timing medications to sustain therapeutic blood levels, and therapeutic drug 
monitoring should be a part of pharmacology content.  Finally, advanced practice registered 
nurses should stay alert to emerging research addressing once daily dosing regimens that may be 




 While an appropriate theoretical basis, reliable scale instruments, data collection 
methods, and an adequate sample size added strength to the study, several limitations of this 





 Limitations related to the sample include the use of a convenience sample and associated 
cross sectional design.  Given the demographic differences between the sample population and 
the U.S. transplant population (see Table 19), results may not be generalizable.  Use of a cross 
sectional design limits the assessment of adherence to one point in time.  Given the opinion that 
all patients are believed to be nonadherent to medication therapy at some point in time, use of 
this design may fail to adequately represent overall adherence rates.  However, given the high 
percentage of nonadherent participants in this study (60.2%), this is most likely a minimal  
limitation. 
The self-report measure of adherence used in this study represents all dimensions of 
medication taking behavior including timing.  Of the participants in this study, 35.7% were 
nonadherent with taking medications within 2 hours of the prescribed time.  By classifying 
participants with timing nonadherence as partially adherent, another dimension is represented 
that may be amenable to intervention.  Dichotomizing adherence results in loss of the 
dimensionality of the concept.   
 Limitations are also associated with the components making up the composite score of 
adherence (CAS) used in measure IST adherence in this study.  The self-report measure of 
adherence (BAASIS) used as a component of this study’s CAS,  runs the risk of under-reporting 
nonadherence as participants may have felt compelled to answer in a manner viewed as positive 
by the investigator.  Given the high rate of self-reported nonadherence (41.8%) as measured by 
this instrument, this is also most likely a minimal limitation.   
Another component of the CAS, clinician collateral reports, were provided by two 





beyond the date of their annual clinic appointment.  In addition, when asked face-to-face by 
clinicians if they are having difficulty taking or getting IST medications (the standard clinic 
adherence assessment in this study setting) participants may be fearful of answering truthfully.  
However, given the observed interactions between clinical professionals and study participants 
as well as other clinic patients, this factor is also felt to be of minimal limitation to this study. 
The final component of the CAS score used in this study was the serum drug assay.  In a 
study assessing the diagnostic accuracy of measurement methods assessing adherence in renal 
transplant patients, the CAS score identified as demonstrating 72.1% specificity in detecting 
nonadherence assessed serum drug assay variability over several serum drug assay values 
(Schäfer-Keller, Steiger, Bock, Denhaerynck, & De Geest, 2008).  The use of a single serum 
drug assay value versus assessing variability over several trough results may have resulted in the 
inappropriate classification of participants with isolated nontherapeutic values as nonadherent.  
This factor is believed by the author to be a major limitation of this study. 
Recommendations for Future Research 
 
Serving as the basis for all future research recommendations is the need for investigators 
to continue to explore factors identified as influencing IST adherence within the context of more 
consistently defined age and time posttransplant groups.  As the adult renal transplant population 
lives longer and continues to age, the influence of modifiable factors impacting adherence may 
change over the lifespan of the recipient.  By intentionally and consistently defining age groups 
and time posttransplant intervals, relevant interventions may be more intently targeted during 





 Given the conflicting research findings regarding the influence of IST medications 
(dosing complexity) on adherence, further research is warranted.  Future research should not 
only explore medication complexity associated with IST medications, but also adherence related 
to other prescribed medications necessary to sustain the health of transplanted grafts (antivirals, 
antihypertensives, hypoglycemic agents, antibiotics).  As both time from transplant and the risk 
for the development of comorbidties associated with long-term IST therapy increases adherence 
to such agents becomes just as critical.  The potential addition of these additional prescribed 
medications adds to the complexity of IST regimens which may increase the risk for 
nonadherence. 
 While research regarding the influence of symptom experience on adherence in European 
transplant recipients is available, lacking are studies conducted within a representative sample of 
the U.S. transplant population.  In addition, further analysis of these studies could help formulate 
symptom profiles specific to IST regimens, gender groups, and ethnic groups. 
 Finally, given the lack of significant findings related to modifiable variables known to 
influence adherence (health beliefs), research exploring the influence of the healthcare system 
(transplant clinic, primary care setting) on adherence. 
Summary and Conclusion 
 
 The purpose of this study was to examine demographics variables, time posttransplant, 
immunosuppressive agents, health beliefs, social support, and symptom experience and test their 
relationship to adherence.  Using a cross sectional design, a convenience sample of 98 long- term 





 The results of this study added to the current body of knowledge in the area of IST 
adherence in adult renal transplant recipients.  Findings from this study can be used to aid 
healthcare personnel involved in the long-term care of adult renal transplant recipients in 
identifying patients at risk for nonadherence.  In addition, given the modifiable nature of social 
support, found to be significantly associated with adherence in this study, healthcare personnel 
can implement interventions appropriate to support participants experiencing lower perceived 
social support.   
 Future research should continue to explore variables known to influence adherence 
within the context of  consistently defined age and time posttransplant groups.  By consistently 
defining groups, cut points could be delineated identifying more focused age groups and time 















Invitation to Participate in Research 
Predictors of Immunosuppressant Adherence 
in Long Term Renal Transplant Recipients 
 
Desired Participants:   Kidney transplant recipients, age 18 at the time 
of transplant. 
 
Research Purpose:  To learn about taking anti-rejection medication 
after kidney transplant.   
 
Participant Commitment: You are being asked to complete five short, 
confidential surveys on the day of your annual clinic appointment.   
There is no cost to you.  All participants will be compensated $25.00 per 
session.   
PARTICIPATION IS LIMITED! 
 
Please notify the clinic receptionist if you are interested in 
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